Radiolabeled pde10a ligands

ABSTRACT

Compounds of formula (I) are disclosed 
     
       
         
         
             
             
         
       
     
     Compounds of formula (I) are useful in treating conditions and disorders prevented by or ameliorated by PDE10A ligands. Radiolabeled compounds of formula (I) are also useful as diagnostic tools as PDE10A positron emission tomography ligands. Also disclosed are pharmaceutical compositions comprising compound of formula (I), methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

CROSS-REFERENCE TO RELATED APPLICATION

This claims priority to U.S. Provisional Patent Application No.61/579,799, filed on Dec. 23, 2011, the contents of which are hereinfully incorporated by reference.

TECHNICAL FIELD

The invention relates to pyrazole derivatives, and more particularly, toradiolabeled pyrazole derivatives, compositions comprising suchcompounds, methods of using such compounds and compositions, andprocesses for preparing such compounds.

BACKGROUND

Cyclic-adenosine monophosphate (cAMP) and cyclic-guanosine monophosphate(cGMP) are second messengers that regulate a vast array of cellularresponses, particularly within the central nervous system. These cyclicnucleotides mediate biological response to extracellular signals (e.g.,hormones, light, neurotransmitters) and influence processes such as ionchannel function, muscle contraction, learning, differentiation,apoptosis, lipogenesis, glycogenolysis, gluconeogenesis, andproinflammatory mediator production and action (Kehler, J., Nielsen, J.,Curr. Pharm. Des. 2011, 17, 137-150).

Phosphodiesterases (PDEs) are a family of enzymes that render cAMP andcGMP inactive through hydrolysis of the cyclic nucleotide3′,5′-phosphodiester bond, and thus play a crucial role in controllingintracellular levels of cAMP/cGMP. Phosphodieasterase-10A (PDE10A), adual-specificity phosphodiesterase, can convert both cAMP to AMP andcGMP to GMP (Loughney, K. et al. Gene 1999, 234, 109-117; Fujishige, K.et al. Eur. J. Biochem. 1999, 266, 1118-1127 and Soderling, S. et al.Proc. Natl. Acad. Sci. 1999, 96, 7071-7076). PDE10A is primarilyexpressed in the brain in the medium spiny neurons of the striatum,nucleus accumbens, and olfactory tubercle (Kotera, J. et al. Biochem.Biophys. Res. Comm. 1999, 261, 551-557 and Seeger, T. F. et al. BrainResearch, 2003, 985, 113-126). These constitute the core of the basalganglia system, which is involved in the regulation of motor,appetitive, and cognitive processes.

The activity of PDE10A can be modified or regulated by theadministration of PDE10A inhibitors. PDE10A inhibitors have therapeuticpotential for the treatment for disorders and conditions mediated inpart by dysfunction of the basal ganglia, other parts of the centralnervous system and other PDE10A expressing tissues. Such disorders andconditions include, but are not limited to, certain psychotic disorderssuch as schizophrenia, positive, negative and/or cognitive symptomsassociated with schizophrenia, delusional disorder or substance-inducedpsychotic disorder, anxiety disorders such as panic disorder,obsessive-compulsive disorder, acute stress disorder or generalizedanxiety disorder, obsessive/compulsive disorders, drug addictions,movement disorders such as Parkinson's disease or restless leg syndrome,cognition deficiency disorders such as Alzheimer's disease ormulti-infarct dementia, mood disorders such as depression or bipolardisorders, or neuropsychiatric conditions such as psychosis,attention-deficit/hyperactivity disorder (ADHD) or related attentionaldisorders. PDE10A inhibitors are also suitable for the treatment ofdiabetes and related disorders such as obesity by regulating the cAMPsignaling system. PDE10A inhibitors might also be useful in preventingneurons from undergoing apoptosis by raising cAMP and cGMP levels and,thus, might possess anti-inflammatory properties. Neurodegenerativedisorders treatable with PDE10A inhibitors include, but are not limitedto, Alzheimer's disease, Huntington's disease, Parkinson's disease,multiple sclerosis, stroke and spinal cord injury. The growth of cancercells is inhibited by cAMP and cGMP. Thus by raising cAMP and cGMP,PDE10A inhibitors can also be used for the treatment of different solidtumors and hematological malignancies such as renal cell carcinoma orbreast cancer.

Although various classes of compounds demonstrating PDE10A inhibitoryactivity exist, it would be beneficial to provide additional compoundsdemonstrating PDE10A modulation that can be incorporated intopharmaceutical compositions useful for therapeutic methods. A usefultool for assessing the ability of a compound to modulate a particularreceptor in humans and animals is positron emission tomography (PET).Positron emission tomography includes the use of positron or gammaemitting radiolabeled compounds to study the interaction between anunlabeled compound and the radiolabeled compound for binding to thereceptor of interest. This information is valuable for clinicalcandidate selection, determination of first-in-human dosing levels,proof of concept studies, and assessment of probability of success of adrug candidate relative to its therapeutic index. The topic and use ofpositron-emitting ligands for this purpose has been generally reviewed,for example in “PET ligands for assessing receptor occupancy in vivo”Burns, et al. Annual Reports in Medicinal Chemistry (2001), 36, 267-276;“Ligand-receptor interactions as studied by PET: implications for drugdevelopment” by Jarmo Hietala, Annals of Medicine (Helsinki) (1999),31(6), 438-443; “Positron emission tomography neuroreceptor imaging as atool in drug discovery, research and development” Burns, et al. CurrentOpinion in Chemical Biology (1999), 3(4), 388-394.

Although compounds potentially useful as PDEA10 PET ligands are known,in general, these tracers suffer from high lipophilicity that can leadto poor specific/nonspecific binding ratios. Furthermore, the kineticsof these tracers and existence of significant quantities ofbrain-penetrant labeled metabolites may hinder their effectiveness forquantitatively evaluating enzyme occupancy in humans. Accordingly, itwould be beneficial to provide additional compounds useful fornoninvasive imaging of PDE10A receptor occupancy in humans and animals.In particular, it would be beneficial to provide PDEA10A PET ligandshaving optimal lipophilicity, protein binding, permeability glycoprotein(P-gp) interaction, free brain concentrations, specific/nonspecificbinding ratios, and human hepatocyte metabolic stability.

SUMMARY

This invention is directed to pyrazole derivatives, and moreparticularly, to radiolabeled pyrazole derivatives, compositionscomprising such compounds, methods of using such compounds andcompositions, and processes for preparing such compounds.

In one aspect, the invention relates to pyrazole derivatives having acompound of formula (I):

or a pharmaceutically acceptable salt, ester, amide, prodrug, orradiolabeled form thereof, whereinR is selected from the group consisting of hydrogen, C₁-C₆ alkyl, andC₃-C₈ cycloalkyl;HetAr is a heteroaryl group selected from the group consisting offormula (i) and formula (ii);

--- is absent or a bond;Z¹, Z², Z³, Z⁴, Z⁵, Z⁸, Z⁹, Z¹⁰, Z¹¹, and Z¹² are each independentlyselected from the group consisting of N and CR²;Z⁶ and Z⁷ are each independently selected from the group consisting ofN, NR¹, CR², CHR³, SO₂, and C═O;Z¹³ is selected from the group consisting of NR¹, CHR³, and O; andR¹, R², and R³ are each independently selected from the group consistingof hydrogen, halogen, C₁-C₆ alkyl, and C₃-C₈ cycloalkyl;provided that at least two of Z¹, Z², Z³, Z⁴, Z⁵, Z⁶, and Z⁷ areheteroatoms; and provided that the following non-radiolabeled compoundsare excluded:

-   2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazoline;    and    1-methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1H-benzo[d]imidazole.

Another aspect of the invention relates to pharmaceutical compositionscomprising compounds of the invention. Such compositions can beadministered in accordance with a method of the invention as part of atherapeutic regimen for treatment or prevention of conditions anddisorders related to PDE10A activity. Such compositions can beadministered in a diagnostic procedure, such as positron emissiontomography (PET) or single photon emission computed tomography (sPECT).

Another aspect of the invention relates to use of the compounds andcompositions of the invention as diagnostic tools. The compounds of theinvention, synthesized with ¹¹C, ¹⁸F, or other positron-emittingisotopes are suitable ligand tools for PET. Especially suitablecompounds of the invention for this use are those wherein a ¹¹CH₃ groupcan be incorporated into the compound by reaction with ¹¹CH₃I. Also,especially suitable compounds of the use are those wherein a ¹⁸F groupcan be incorporated into the compound by reaction with ¹⁸F-fluorideanion. The incorporation of ¹¹CH₃ can be carried out according to amethod known to those skilled in the art. According to one method,compounds of formula (I) can be treated with base and an alkyl iodidesuch as ¹¹CH₃I to prepare ligands for use in PET studies. Forincorporation of ¹⁸F into compounds or compositions of the invention,compounds of formula (I) can be treated with methanesulfonic anhydrideor triflic anhydride and a base in an inert solvent such asdichloromethane, and the resulting compound (a methanesulfonate ortriflate) can be treated with ¹⁸F-fluoride by methods well known toskilled in the art of synthetic organic chemistry or medicinalchemistry.

Yet another aspect of the invention relates to a method of selectivelymodulating PDE10A activity. The method is useful for treating, orpreventing conditions and disorders related to PDE10A modulation inmammals. More particularly, the method is useful for treating orpreventing conditions and disorders related to central nervous systemfunction, including memory, cognition processes and neurologicalprocesses.

Processes for making compounds of the invention also are contemplated.

The compounds, compositions comprising the compounds, methods for makingthe compounds, methods for treating or preventing conditions anddisorders by administering the compounds, radiolabeled forms of thecompounds, compositions containing radiolabeled forms of the compounds,and methods of using radiolabeled forms of the compounds are furtherdescribed herein.

DETAILED DESCRIPTION Definition of Terms

Certain terms as used in the specification are intended to refer to thefollowing definitions, as detailed below.

The term “acyl” as used herein means an alkyl group, as defined herein,appended to the parent molecular moiety through a carbonyl group, asdefined herein. Representative examples of acyl include, but are notlimited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl,and 1-oxopentyl.

The term “acyloxy” as used herein means an acyl group, as definedherein, appended to the parent molecular moiety through an oxygen atom.Representative examples of acyloxy include, but are not limited to,acetyloxy, propionyloxy, and isobutyryloxy.

The term “alkenyl” as used herein means a straight or branched chainhydrocarbon containing from 2 to 10 carbons, and preferably 2, 3, 4, 5,or 6 carbons, and containing at least one carbon-carbon double bond.Representative examples of alkenyl include, but are not limited to,ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl,5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

The term “alkoxy” as used herein means an alkyl group, as definedherein, appended to the parent molecular moiety through an oxygen atom.Representative examples of alkoxy include, but are not limited to,methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, andhexyloxy.

The term “alkoxyalkoxy” as used herein means an alkoxy group, as definedherein, appended to the parent molecular moiety through another alkoxygroup, as defined herein. Representative examples of alkoxyalkoxyinclude, but are not limited to, tert-butoxymethoxy, 2-ethoxyethoxy,2-methoxyethoxy, and methoxymethoxy.

The term “alkoxyalkyl” as used herein means an alkoxy group, as definedherein, appended to the parent molecular moiety through an alkyl group,as defined herein. Representative examples of alkoxyalkyl include, butare not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl,and methoxymethyl.

The term “alkoxycarbonyl” as used herein means an alkoxy group, asdefined herein, appended to the parent molecular moiety through acarbonyl group, as defined herein. Representative examples ofalkoxycarbonyl include, but are not limited to, methoxycarbonyl,ethoxycarbonyl, and tert-butoxycarbonyl.

The term “alkoxyimino” as used herein means an alkoxy group, as definedherein, appended to the parent molecular moiety through an imino group,as defined herein. Representative examples of alkoxyimino include, butare not limited to, ethoxy(imino)methyl and methoxy(imino)methyl.

The term “alkoxysulfonyl” as used herein means an alkoxy group, asdefined herein, appended to the parent molecular moiety through asulfonyl group, as defined herein. Representative examples ofalkoxysulfonyl include, but are not limited to, methoxysulfonyl,ethoxysulfonyl, and propoxysulfonyl.

The term “alkyl” as used herein means a straight or branched chainhydrocarbon containing from 1 to 10 carbon atoms, and preferably 1, 2,3, 4, 5, or 6 carbons. Representative examples of alkyl include, but arenot limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl,iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl,3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl,n-octyl, n-nonyl, and n-decyl. Each of the carbon atoms of the alkylgroup is substituted with hydrogen or with 0, 1, or 2 substituentsselected from acyl, acyloxy, alkoxy, alkoxyalkoxy, alkoxyalkyl,alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkylcarbonyl,alkylsulfonyl, amido, carboxy, cyano, cycloalkyl, fluoroalkoxy, formyl,haloalkoxy, haloalkyl, halogen, hydroxy, hydroxyalkyl, mercapto, nitro,oxo, alkylthio, NR_(A)R_(B), (NR_(A)R_(B))carbonyl,(NR_(A)R_(B))sulfonyl, —OS(O)₂-alkyl, and —OS(O)₂-aryl.

The term “alkylene” means a divalent group derived from a straight orbranched chain hydrocarbon of from 1 to 10 carbon atoms. Representativeexamples of alkylene include, but are not limited to, —CH₂—, —CH(CH)—,—C(CH₃)₂—, —CH₂CH₂—, —CH₂CH₂CH₂—, CH₂CH₂CH₂CH₂—, and —CH₂CH(CH)CH₂—.

The term “alkylamino” as used herein means an alkyl group, as definedherein, appended to the parent molecular moiety through a NH group.Representative examples of alkylamino include, but are not limited to,methylamino, ethylamino, isopropylamino, and butylamino.

The term “alkylcarbonyl” as used herein means an alkyl group, as definedherein, appended to the parent molecular moiety through a carbonylgroup, as defined herein. Representative examples of alkylcarbonylinclude, but are not limited to, methylcarbonyl, ethylcarbonyl,isopropylcarbonyl, n-propylcarbonyl, and the like.

The term “alkylsulfonyl” as used herein means an alkyl group, as definedherein, appended to the parent molecular moiety through a sulfonylgroup, as defined herein. Representative examples of alkylsulfonylinclude, but are not limited to, methylsulfonyl and ethylsulfonyl.

The term “alkylthio” as used herein, means an alkyl group, as definedherein, appended to the parent molecular moiety through a sulfur atom.Representative examples of alkylthio include, but are not limited,methylthio, ethylthio, tert-butylthio, and hexylthio.

The term “alkynyl” as used herein means a straight or branched chainhydrocarbon group containing from 2 to 10 carbon atoms, and preferably2, 3, 4, or 5 carbons, and containing at least one carbon-carbon triplebond. Representative examples of alkynyl include, but are not limitedto, acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and1-butynyl.

The term “amido” as used herein means an amino, alkylamino, ordialkylamino group appended to the parent molecular moiety through acarbonyl group, as defined herein. Representative examples of amidoinclude, but are not limited to, aminocarbonyl, methylaminocarbonyl,dimethylaminocarbonyl, and ethylmethylaminocarbonyl.

The term “amino” as used herein means an —NH₂ group.

The term “aryl,” as used herein, means phenyl, a bicyclic aryl, or atricyclic aryl. The bicyclic aryl is attached to the parent molecularmoiety through any carbon atom contained within the bicyclic aryl.Representative examples of the bicyclic aryl include, but are notlimited to, dihydroindenyl, indenyl, naphthyl, dihydronaphthalenyl, andtetrahydronaphthalenyl. The tricyclic aryl is a tricyclic aryl ringsystem such as anthracene or phenanthrene, a bicyclic aryl fused to acycloalkyl, a bicyclic aryl fused to a cycloalkenyl, or a bicyclic arylfused to a phenyl. The tricyclic aryl is attached to the parentmolecular moiety through any carbon atom contained within the tricyclicaryl. Representative examples of tricyclic aryl ring include, but arenot limited to, anthracenyl, phenanthrenyl, azulenyl,dihydroanthracenyl, fluorenyl, and tetrahydrophenanthrenyl.

The carbon atoms of the aryl groups of this invention are substitutedwith hydrogen or are optionally substituted with one or moresubstituents independently selected from acyl, acyloxy, alkenyl, alkoxy,alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl,alkyl, alkylcarbonyl, alkylsulfonyl, alkynyl, amido, carboxy, cyano,cycloalkyl, fluoroalkoxy, formyl, haloalkoxy, haloalkyl, halogen,hydroxy, hydroxyalkyl, mercapto, nitro, alkylthio, —NR_(A)R_(B),(NR_(A)R_(B))carbonyl, —SO₂N(R_(14a)) (R_(14b)), andN(R_(14a))SO₂(R_(14b)). Where the aryl group is a phenyl group, thenumber of substituents is 0, 1, 2, 3, 4, or 5. Where the aryl group is abicyclic aryl, the number of substituents is 0, 1, 2, 3, 4, 5, 6, 7, 8,or 9. Where the aryl group is a tricyclic aryl, the number ofsubstituents is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9.

The term “arylalkyl” as used herein means an aryl group, as definedherein, appended to the parent molecular moiety through an alkyl group,as defined herein. Representative examples of arylalkyl include, but arenot limited to, benzyl, 2-phenylethyl and 3-phenylpropyl.

The term “carbonyl” as used herein means a —C(═O)— group.

The term “carboxy” as used herein means a —CO₂H group, which may beprotected as an ester group —CO₂-alkyl.

The term “cyano” as used herein means a —CN group, attached to theparent molecular moiety through the carbon.

The term “cyanophenyl” as used herein means a —CN group appended to theparent molecular moiety through a phenyl group, including, but notlimited to, 4-cyanophenyl, 3-cyanophenyl, and 2-cyanophenyl.

The term “cycloalkyl” as used herein means a saturated cyclichydrocarbon group containing from 3 to 8 carbons. Examples of cycloalkylinclude cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,and cyclooctyl.

Each of the carbon atoms of the cycloalkyl groups of the invention issubstituted with 0, 1, or 2 substituents selected from acyl, acyloxy,alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino,alkoxysulfonyl, alkyl, alkylcarbonyl, alkylsulfonyl, alkynyl, amido,carboxy, cyano, cycloalkyl, fluoroalkoxy, formyl, haloalkoxy, haloalkyl,halogen, hydroxy, hydroxyalkyl, mercapto, nitro, alkylthio,—NR_(A)R_(B), (NR_(A)R_(B))carbonyl, —SO₂N(R_(14a)) (R_(14b)), andN(R_(14a))SO₂(R_(14b)).

The term “cycloalkylcarbonyl” as used herein means a cycloalkyl group,as defined herein, appended to the parent molecular moiety through acarbonyl group, as defined herein. Representative examples ofcycloalkylcarbonyl include, but are not limited to, cyclopropylcarbonyl,cyclopentylcarbonyl, cyclohexylcarbonyl, and cycloheptylcarbonyl.

The term “dialkylamino” as used herein means two independent alkylgroups, as defined herein, appended to the parent molecular moietythrough a nitrogen atom. Representative examples of dialkylaminoinclude, but are not limited to, dimethylamino, diethylamino,ethylmethylamino, and butylmethylamino.

The term “fluoro” as used herein means —F.

The term “fluoroalkyl” as used herein means at least one fluoro group,as defined herein, appended to the parent molecular moiety through analkyl group, as defined herein. Representative examples of fluoroalkylinclude, but are not limited to, fluoromethyl, difluoromethyl,trifluoromethyl, pentafluoroethyl, 2-fluoroethyl, and2,2,2-trifluoroethyl.

The term “fluoroalkoxy” as used herein means at least one fluoro group,as defined herein, appended to the parent molecular moiety through analkoxy group, as defined herein. Representative examples of fluoroalkoxyinclude, but are not limited to, fluoromethoxy, difluoromethoxy,trifluoromethoxy, pentafluoroethoxy, heptafluoropropyloxy, and2,2,2-trifluoroethoxy.

The term “formyl” as used herein means a —C(O)H group.

The term “halo” or “halogen” as used herein means Cl, Br, I, or F.

The term “haloalkoxy” as used herein means at least one halogen, asdefined herein, appended to the parent molecular moiety through analkoxy, as defined herein. Representative examples of haloalkoxyinclude, but are not limited to, 2-fluoroethoxy, trifluoromethoxy, andpentafluoroethoxy.

The term “haloalkyl” as used herein means at least one halogen, asdefined herein, appended to the parent molecular moiety through an alkylgroup, as defined herein. Representative examples of haloalkyl include,but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl,pentafluoroethyl, and 2-chloro-3-fluoropentyl.

The term “heterocycle”, as used herein, refers to aromatic ornon-aromatic cyclic groups that contain at least one heteroatom.Examples of aromatic heterocycles are, for example, heteroaryl groups asfurther defined below. Non-aromatic heterocycles are non-aromatic cyclicgroups that contain at least one heteroatom; examples of non-aromaticheterocyclic groups or non-aromatic heterocycles are further definedbelow. Heterocyclic rings are connected to the parent molecular moietythrough a carbon atom, or alternatively in the case of heterocyclicrings that contain a bivalent nitrogen atom having a free site forattachment, the heterocyclic ring may be connected to the parentmolecular moiety though a nitrogen atom. Additionally, the heterocyclesmay be present as tautomers.

The term “heteroaryl”, as used herein, refers to an aromatic ringcontaining one or more heteroatoms independently selected from nitrogen,oxygen, or sulfur, or a tautomer thereof. Such rings can be monocyclicor bicyclic as further described herein.

The terms “monocyclic heteroaryl” or “5- or 6-membered heteroaryl ring”,as used herein, refer to 5- or 6-membered aromatic rings containing 1,2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, orsulfur, or a tautomer thereof. Examples of such rings include, but arenot limited to, a ring wherein one carbon is replaced with an O or Satom; one, two, or three N atoms are arranged in a suitable manner toprovide an aromatic ring; or a ring wherein two carbon atoms in the ringare replaced with one O or S atom and one N atom. Such rings caninclude, but are not limited to, a six-membered aromatic ring whereinone to four of the ring carbon atoms are replaced by nitrogen atoms,five-membered rings containing a sulfur, oxygen, or nitrogen in thering; five-membered rings containing one to four nitrogen atoms; andfive-membered rings containing an oxygen or sulfur and one to threenitrogen atoms. Representative examples of 5- to 6-membered heteroarylrings include, but are not limited to, furyl, imidazolyl, isoxazolyl,isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl,pyrimidinyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiadiazolonyl,thiadiazinonyl, oxadiazolyl, oxadiazolonyl, oxadiazinonyl, thiazolyl,thienyl, triazinyl, triazolyl, triazolyl, pyridazinonyl, pyridonyl, andpyrimidinonyl.

The term “bicyclic heteroaryl” or “8- to 12-membered bicyclic heteroarylring”, as used herein, refers to an 8-, 9-, 10-, 11-, or 12-memberedbicyclic aromatic ring containing at least 3 double bonds, and whereinthe atoms of the ring include one or more heteroatoms independentlyselected from oxygen, sulfur, and nitrogen. Representative examples ofbicyclic heteroaryl rings include indolyl, benzothienyl, benzofuranyl,indazolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl,benzoisothiazolyl, benzoisoxazolyl, quinolinyl, isoquinolinyl,quinazolinyl, quinoxalinyl, phthalazinyl, pteridinyl, purinyl,naphthyridinyl, cinnolinyl, thieno[2,3-d]imidazole,1,5-dihydro-benzo[b][1,4]diazepin-2-on-yl, and pyrrolopyrimidinyl.

Heteroaryl groups of the invention, whether monocyclic or bicyclic, maybe substituted with hydrogen, or optionally substituted with one or moresubstituents independently selected from acyl, acyloxy, alkenyl, alkoxy,alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl,alkyl, alkylcarbonyl, alkylsulfonyl, alkynyl, amido, carboxy, cyano,cycloalkyl, fluoroalkoxy, formyl, haloalkoxy, haloalkyl, halogen,hydroxy, hydroxyalkyl, mercapto, nitro, oxo, alkylthio, —NR_(A)R_(B),(NR_(A)R_(B))carbonyl, —SO₂N(R_(14a)) (R_(14b)), andN(R_(14a))SO₂(R_(14b)). Monocyclic heteroaryl or 5- or 6-memberedheteroaryl rings are substituted with 0, 1, 2, 3, 4, or 5 substituents.Bicyclic heteroaryl or 8- to 12-membered bicyclic heteroaryl rings aresubstituted with 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9 substituents.Heteroaryl groups of the present invention may be present as tautomers.

The terms “non-aromatic heterocyclic ring” and “non-aromaticheterocycle”, as used herein, refer to a 4- to 12-membered monocyclic orbicyclic ring containing at least one saturated carbon atom, and alsocontaining one, two, three, four, or five heteroatoms independentlyselected from the group consisting of nitrogen, oxygen, and sulfur.Four- and five-membered rings may have zero or one double bond.Six-membered rings may have zero, one, or two double bonds. Seven- andeight-membered rings may have zero, one, two, or three double bonds. Thenon-aromatic heterocycle groups of the invention can be attached througha carbon atom or a nitrogen atom. The non-aromatic heterocycle groupsmay be present in tautomeric form. Representative examples ofnitrogen-containing heterocycles include, but are not limited to,azepanyl, azetidinyl, aziridinyl, azocanyl, morpholinyl, piperazinyl,piperidinyl, pyrrolidinyl, pyrrolinyl, dihydrothiazolyl,dihydropyridinyl, and thiomorpholinyl. Representative examples ofnon-nitrogen containing non-aromatic heterocycles include, but are notlimited to, dioxanyl, dithianyl, tetrahydrofuryl, dihydropyranyl,tetrahydropyranyl, and [1,3]dioxolanyl.

The non-aromatic heterocycles of the invention may be substituted withhydrogen, or optionally substituted with 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9substituents independently selected from acyl, acyloxy, alkenyl, alkoxy,alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl,alkyl, alkylcarbonyl, alkylsulfonyl, alkynyl, amido, carboxy, cyano,cycloalkyl, fluoroalkoxy, formyl, haloalkoxy, haloalkyl, halogen,hydroxy, hydroxyalkyl, mercapto, nitro, oxo, alkylthio, —NR_(A)R_(B),(NR_(A)R_(B))carbonyl, —SO₂N(R_(14a)) (R_(14b)), andN(R_(14a))SO₂(R_(14b)).

Additional examples of heterocycles include, but are not limited to,isoindoline-1,3-dione, (Z)-1H-benzo[e][1,4]diazepin-5(4H)-one,pyrimidine-2,4(1H,3H)-dione, benzo[d]thiazol-2(3H)-one,pyridin-4(1H)-one, imidazolidin-2-one, 1H-imidazol-2(3H)-one,pyridazin-3(2H)-one, tetrahydropyrimidin-2(1H)-one, and1H-benzo[d]imidazol-2(3H)-one.

The term “heterocyclealkyl” as used herein means a heterocycle group, asdefined herein, appended to the parent molecular moiety through an alkylgroup, as defined herein. Representative examples of heterocyclealkylinclude, but are not limited to, 2-thienylmethyl, 2-thienylethyl,2-furylethyl, and 2-furylmethyl.

The term “hydroxy” as used herein means an —OH group.

The term “hydroxyalkyl” as used herein means at least one hydroxy group,as defined herein, appended to the parent molecular moiety through analkyl group, as defined herein. Representative examples of hydroxyalkylinclude, but are not limited to, hydroxymethyl, 2-hydroxyethyl,2-methyl-2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and2-ethyl-4-hydroxyheptyl.

The term “hydroxy-protecting group” means a substituent which protectshydroxyl groups against undesirable reactions during syntheticprocedures. Examples of hydroxy-protecting groups include, but are notlimited to, methoxymethyl, benzyloxymethyl, 2-methoxyethoxymethyl,2-(trimethylsilyl)ethoxymethyl, benzyl, triphenylmethyl,2,2,2-trichloroethyl, t-butyl, trimethylsilyl, t-butyldimethylsilyl,t-butyldiphenylsilyl, methylene acetal, acetonide benzylidene acetal,cyclic ortho esters, methoxymethylene, cyclic carbonates, and cyclicboronates. Hydroxy-protecting groups are appended onto hydroxy groups byreaction of the compound that contains the hydroxy group with a base,such as triethylamine, and a reagent selected from an alkyl halide,alkyl trifilate, trialkylsilyl halide, trialkylsilyl triflate,aryldialkylsilyltriflate, or an alkylchloroformate, CH₂I₂, or adihaloboronate ester, for example with methyliodide, benzyl iodide,triethylsilyltriflate, acetyl chloride, benzylchloride, ordimethylcarbonate. A protecting group also may be appended onto ahydroxy group by reaction of the compound that contains the hydroxygroup with acid and an alkyl acetal.

The term “imino” as defined herein means a —C(═NH)— group.

The term “mercapto” as used herein means a —SH group.

The term “(NR_(A)R_(B))” as used herein means an amino group substitutedby R_(A) and R_(B). R_(A) and R_(B) are independently selected fromhydrogen, alkyl, acyl, cycloalkyl, and formyl.

The term “(NR_(A)R_(B))alkyl” as used herein means an —NR_(A)R_(B)group, as defined herein, appended to the parent molecular moietythrough an alkyl group, as defined herein. Representative examples of(NR_(A)R_(B))alkyl include, but are not limited to,2-(methylamino)ethyl, 2-(dimethylamino)ethyl, 2-(amino)ethyl,2-(ethylmethylamino)ethyl, and the like.

The term “(NR_(A)R_(B))carbonyl” as used herein means an —NR_(A)R_(B)group, as defined herein, appended to the parent molecular moietythrough a carbonyl group, as defined herein. Representative examples of(NR_(A)R_(B))carbonyl include, but are not limited to, aminocarbonyl,(methylamino)carbonyl, (dimethylamino)carbonyl,(ethylmethylamino)carbonyl, and the like.

The term “(NR_(A)R_(B))sulfonyl” as used herein means a —NR_(A)R_(B)group, as defined herein, appended to the parent molecular moietythrough a sulfonyl group, as defined herein. Representative examples of(NR_(A)R_(B))sulfonyl include, but are not limited to, aminosulfonyl,(methylamino)sulfonyl, (dimethylamino)sulfonyl and(ethylmethylamino)sulfonyl.

The term “—N(R_(14a))SO₂(R_(14b))” as used herein means an amino groupattached to the parent moiety to which is further appended with anR_(14a) group as defined herein, and a SO₂ group to which is appended an(R_(14b)) group as defined herein. R_(14a) and R_(14b) are eachindependently hydrogen, alkyl, or cycloalkyl. Representative examples of—N(R_(14a))SO₂(R_(14b)) include, but are not limited to,N-methylmethanesulfonamide.

The term “—SO₂N(R_(14a))(R_(14b))” as used herein means aN(R_(14a))(R_(14b)) group attached to a SO₂ group, appended to theparent moiety through the sulfonyl group. R_(14a) and R_(14b) are eachindependently hydrogen, alkyl, or cycloalkyl. Representative examples ofSO₂N(R_(14a))(R_(14b)) include, but are not limited to(dimethylamino)sulfonyl and N-cyclohexyl-N-methylsulfonyl.

The term “nitro” as used herein means a —NO₂ group.

The term “nitrogen protecting group” as used herein means those groupsintended to protect a nitrogen atom against undesirable reactions duringsynthetic procedures. Nitrogen protecting groups comprise carbamates,amides, N-benzyl derivatives, and imine derivatives. Preferred nitrogenprotecting groups are acetyl, benzoyl, benzyl, benzyloxycarbonyl (Cbz),formyl, phenylsulfonyl, pivaloyl, tert-butoxycarbonyl (Boc),tert-butylacetyl, trifluoroacetyl, and triphenylmethyl (trityl).Nitrogen-protecting groups are appended onto primary or secondary aminogroups by reacting the compound that contains the amine group with base,such as triethylamine, and a reagent selected from an alkyl halide, analkyl trifilate, a dialkyl anhydride, for example as represented by analkyl anhydride (alkyl-OC═O)₂O, a diaryl anhydride, for example asrepresented by (aryl-OC═O)₂O, an acyl halide, an alkylchloroformate, oran alkylsulfonylhalide, an arylsulfonylhalide, or halo-CON(alkyl)₂, forexample acetylchloride, benzoylchloride, benzylbromide,benzyloxycarbonylchloride, formylfluoride, phenylsulfonylchloride,pivaloylchloride, (tert-butyl-O—C═O)₂O, trifluoroacetic anhydride, andtriphenylmethylchloride.

The term “oxo” as used herein means (═O).

The term “sulfonyl” as used herein means a —S(O)₂— group.

The term “radiolabel” as used herein refers to a compound of theinvention in which at least one of the atoms is a radioactive atom orradioactive isotope, wherein the radioactive atom or isotopespontaneously emits gamma rays or energetic particles, for example alphaparticles or beta particles, or positrons. Examples of such radioactiveatoms include, but are not limited to, ³H (tritium), ¹⁴C, ¹¹C, ¹⁵O, ¹⁸F,³⁵S, ¹²³I, and ¹²⁵I.

Compounds of the Invention

Compounds of formula (I) are disclosed,

wherein HetAr and R are as described in the Summary of the Invention.

In certain embodiments, the compounds of formula (I) are radiolabeled.

In certain embodiments, R comprises a radiolabeled substituent group.Preferably, R comprises a [¹¹C]-radiolabeled or a [¹⁸F]-radiolabeledsubstituent group. More preferably, R is selected from [¹¹C]methyl and2-[¹⁸F]fluoroethyl.

In certain embodiments, HetAr comprises a radiolabeled substituentgroup.

Preferably, HetAr comprises a [¹¹C]-radiolabeled or a [¹⁸F]-radiolabeledsubstituent group. More preferably, HetAr comprises a radiolabeled groupselected from [¹¹C]methyl and 2-[¹⁸F]fluoroethyl.

In certain embodiments, HetAr is a heteroaryl group selected from thegroup consisting of

wherein Z¹, Z⁸, Z¹³, and R¹ are as defined in the Summary of theInvention.

In certain embodiments, HetAr is a heteroaryl group of formula (a),

wherein R is selected from the group consisting of hydrogen, C₁-C₆alkyl, and C₃-C₈ cycloalkyl. Preferably, R is C₁-C₆ alkyl. Morepreferably, R is methyl or 2-fluoroethyl. Most preferably, R is[¹¹C]methyl or 2-[¹⁸F]fluoroethyl.

In certain embodiments, HetAr is a heteroaryl group of formula (b),

wherein R is selected from the group consisting of hydrogen, C₁-C₆alkyl, and C₃-C₈ cycloalkyl. Preferably, R is C₁-C₆ alkyl. Morepreferably, R is methyl or 2-fluoroethyl. Most preferably, R is[¹¹C]methyl or 2-[¹⁸F]fluoroethyl.

In certain embodiments, HetAr is a heteroaryl group of formula (c),

wherein R is selected from the group consisting of hydrogen, C₁-C₆alkyl, and C₃-C₈ cycloalkyl. Preferably, R is C₁-C₆ alkyl. Morepreferably, R is methyl or 2-fluoroethyl. Most preferably, R is[¹¹C]methyl or 2-[¹⁸F]fluoroethyl.

In certain embodiments, HetAr is a heteroaryl group of formula (d),

wherein R is selected from the group consisting of hydrogen, C₁-C₆alkyl, and C₃-C₈ cycloalkyl. Preferably, R is C₁-C₆ alkyl. Morepreferably, R is methyl or 2-fluoroethyl. Most preferably, R is[¹¹C]methyl or 2-[¹⁸F]fluoroethyl.

In certain embodiments, HetAr is a heteroaryl group of formula (e),

wherein R is selected from the group consisting of hydrogen, C₁-C₆alkyl, and C₃-C₈ cycloalkyl. Preferably, R is C₁-C₆ alkyl. Morepreferably, R is methyl or 2-fluoroethyl. Most preferably, R is[¹¹C]methyl or 2-[¹⁸F]fluoroethyl.

In certain embodiments, HetAr is a heteroaryl group of formula (f),

wherein R is selected from the group consisting of hydrogen, C₁-C₆alkyl, and C₃-C₈ cycloalkyl; Z¹ is N or CH; and R¹ is selected from thegroup consisting of hydrogen, C₁-C₆ alkyl, and C₃-C₈ cycloalkyl.Preferably, R is C₁-C₆ alkyl and R¹ is C₁-C₆ alkyl. More preferably, atleast one of R and R¹ is methyl or 2-fluoroethyl. Most preferably, oneof R and R¹ is [¹¹C]methyl or 2-[¹⁸F]fluoroethyl.

In certain embodiments, HetAr is a heteroaryl group of formula (g),

wherein R is selected from the group consisting of hydrogen, C₁-C₆alkyl, and C₃-C₈ cycloalkyl; Z¹ is N or CH; and R¹ is selected from thegroup consisting of hydrogen, C₁-C₆ alkyl, and C₃-C₈ cycloalkyl.Preferably, R is C₁-C₆ alkyl and R¹ is C₁-C₆ alkyl. More preferably, atleast one of R and R¹ is methyl or 2-fluoroethyl. Most preferably, oneof R and R¹ is [¹¹C]methyl or 2-[¹⁸F]fluoroethyl.

In certain embodiments, HetAr is a heteroaryl group of formula (h),

wherein R is selected from the group consisting of hydrogen, C₁-C₆alkyl, and C₃-C₈ cycloalkyl; Z⁸ is N or CH; Z¹³ is NR¹, CHR³, or O; R¹is selected from the group consisting of hydrogen, C₁-C₆ alkyl, andC₃-C₈ cycloalkyl; and R³ is selected from the group consisting ofhydrogen, C₁-C₆ alkyl, and C₃-C₈ cycloalkyl. Preferably, when Z¹³ is O,R is C₁-C₆ alkyl, more preferably R is methyl or 2-fluoroethyl, and mostpreferably R is [¹¹C]methyl or 2-[¹⁸F]fluoroethyl. Preferably, when Z¹³is NR¹, R is C₁-C₆ alkyl and R¹ is C₁-C₆ alkyl, more preferably at leastone of R and R¹ is methyl or 2-fluoroethyl, and most preferably one of Rand R¹ is [¹¹C]methyl or 2-[¹⁸F]fluoroethyl. Preferably, when Z¹³ isCHR³, R is C₁-C₆ alkyl and R³ is C₁-C₆ alkyl, more preferably at leastone of R and R³ is methyl or 2-fluoroethyl, and most preferably one of Rand R³ is [¹¹C]methyl or 2-[¹⁸F]fluoroethyl.

Specific embodiments contemplated as part of the invention also include,but are not limited to, compounds of formula (I), as defined, forexample:

-   2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;-   2-((4-(1-(2-fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;-   2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,6-naphthyridine;-   2-((4-(1-(2-fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,6-naphthyridine;-   6-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-c]pyridazine;-   6-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-c]pyridazine;-   2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazoline;-   2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine;-   2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine;-   3-methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;-   2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methylquinazolin-4(3H)-one;-   3-(2-fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;-   3-methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;-   2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methylpyrido[3,2-d]pyrimidin-4(3H)-one;-   3-(2-fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;-   1,1-dioxo-2-methyl-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   1,1-dioxo-2-methyl-3-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   1,1-dioxo-2-(2-fluoroethyl)-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole;-   2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole;-   2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1-methyl-1H-benzo[d]imidazole;-   1-(2-fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1H-benzo[d]imidazole;-   2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)oxazolo[5,4-b]pyridine;-   2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)oxazolo[5,4-b]pyridine;-   3-methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;-   2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methyl-3H-imidazo[4,5-b]pyridine;-   3-(2-fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;-   2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;-   2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,6-naphthyridine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,6-naphthyridine;-   6-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-c]pyridazine;-   6-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-c]pyridazine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazoline;-   2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine;-   3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methylquinazolin-4(3H)-one;-   3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;-   3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;-   3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methylpyrido[3,2-d]pyrimidin-4(3H)-one;-   3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;-   3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;-   1,1-dioxo-2-methyl-3-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   1,1-dioxo-2-methyl-3-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   1,1-dioxo-2-[¹¹C]methyl-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   1,1-dioxo-2-(2-[¹⁸F]fluoroethyl)-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1-methyl-1H-benzo[d]imidazole;-   1-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1H-benzo[d]imidazole;-   2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)oxazolo[5,4-b]pyridine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)oxazolo[5,4-b]pyridine;-   3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methyl-3H-imidazo[4,5-b]pyridine;-   3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;-   3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;    and-   2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-5-[³H]benzo[d]oxazole.

Compounds of the invention may exist as stereoisomers wherein,asymmetric or chiral centers are present. These stereoisomers are “R” or“S” depending on the configuration of substituents around the chiralcarbon atom. The terms “R” and “S” used herein are configurations asdefined in IUPAC 1974 Recommendations for Section E, FundamentalStereochemistry, in Pure Appl. Chem., 1976, 45: 13-30. The inventioncontemplates various stereoisomers and mixtures thereof and these arespecifically included within the scope of this invention. Stereoisomersinclude enantiomers and diastereomers, and mixtures of enantiomers ordiastereomers. Individual stereoisomers of compounds of the inventionmay be prepared synthetically from commercially available startingmaterials which contain asymmetric or chiral centers or by preparationof racemic mixtures followed by resolution well-known to those ofordinary skill in the art. These methods of resolution are exemplifiedby (1) attachment of a mixture of enantiomers to a chiral auxiliary,separation of the resulting mixture of diastereomers byrecrystallization or chromatography and optional liberation of theoptically pure product from the auxiliary as described in Furniss,Hannaford, Smith, and Tatchell, “Vogel's Textbook of Practical OrganicChemistry”, 5th edition (1989), Longman Scientific & Technical, EssexCM20 2JE, England, or (2) direct separation of the mixture of opticalenantiomers on chiral chromatographic columns or (3) fractionalrecrystallization methods.

Compounds of the invention may exist as cis or trans isomers, whereinsubstituents on a ring may attached in such a manner that they are onthe same side of the ring (cis) relative to each other, or on oppositesides of the ring relative to each other (trans). Individual cis ortrans isomers of compounds of the invention may be preparedsynthetically from commercially available starting materials usingselective organic transformations, or by prepared in single isomericform by purification of mixtures of the cis and trans isomers. Suchmethods are well-known to those of ordinary skill in the art, and mayinclude separation of isomers by recrystallization or chromatography.

It should be understood that the compounds of the invention may possesstautomeric forms, as well as geometric isomers, and that these alsoconstitute an aspect of the invention. It is also understood that thecompounds of the invention may exist as isotopomers, wherein atoms mayhave different weights; for example, hydrogen and deuterium, or ¹¹C, ¹²Cand ¹³C.

Methods for Preparing Compounds of the Invention

The compounds of the invention can be better understood in connectionwith the following synthetic schemes and methods which illustrate ameans by which the compounds can be prepared.

The compounds of this invention can be prepared by a variety ofsynthetic procedures. Representative procedures are shown in, but arenot limited to, Schemes 1-9.

[¹¹C]methylated compounds of formula (2), wherein HetAr is as defined informula (I), can be prepared as described in Scheme 1. Des-methylcompounds of formula (1), prepared using methodologies described hereinor known to those of ordinary skill in the art, when treated with[¹¹C]methyl iodide in the presence of a base will provide compounds offormula (2). A mixture of isomers resulting from ¹¹C-methylation ateither of the pyrazole nitrogens can be separated chromatographically.The [¹¹C]methyl iodide can be prepared by methodologies known to thoseof ordinary skill in the art, such as for example, by halogenation of¹¹C methane in a gas phase process, or by reducing cyclotron-produced[¹¹C]carbon dioxide with lithium aluminum hydride followed by hydriodicacid treatment.

Des-methyl compounds of formula (1) can be prepared as described inScheme 2. Treatment of 4-methylpyridine with lithium diisopropylamide(LDA) followed by 4-(benzyloxy)-N-methoxy-N-methylbenzamide will providea compound of formula (3). The 4-(benzyloxy)-N-methoxy-N-methylbenzamidecan be prepared by reacting 4-(benzyloxy)benzoyl chloride withN,O-dimethylhydroxylamine hydrochloride in the presence oftriethylamine. The benzyl group of the compound of formula (3) can beremoved via treatment with hydrogen over palladium/carbon, therebyproviding phenolic compounds of formula (4). Using standard Mitsunobureaction conditions known to those skilled in the art and widelyavailable in the literature, reaction between compounds of formula (4)and heteroaromatic methanol compounds of formula (5) will providecompounds of formula (6). The heteroaromatic compounds of formula (5)may be selected from commercially available compounds or compoundsobtainable by methods known in the art. Optionally, heteroaromaticcompounds of formula (5) can be prepared from hydrolysis of commerciallyavailable halomethylheteroaryls or from reduction ofheteroarylcarbaldehydes. If the appropriate halomethylheteroaryls orheteroarylcarbaldehydes are not commercially available, either may beprepared from the corresponding methyl substituted heteroaryl compoundby treatment with N-bromosuccinimide (NBS) or N-chlorosuccinimide (NCS)for the halomethyl compounds, or with selenium dioxide for thecarbaldehydes. Treatment of compounds of formula (6) with1,1-dimethoxy-N,N-dimethylmethanamine will provide compounds of formula(7). Compounds of formula (7), when treated with hydrazine, will providecompounds of formula (1).

Compounds of formula (9) wherein HetAr includes a ¹¹C-label can beprepared as described in Scheme 3. Compounds of formula (8), whereinHetAr comprises a functional group capable of undergoing alkylation(e.g., a primary or secondary amine), when treated with [¹¹C]methyliodide in the presence of a base will provide heteroaromatic compoundsof formula (9) comprising a carbon-radiolabel. In instances where thepyrazole nitrogen is unsubstituted (i.e., R═H), radiolabeling can alsooccur at the pyrazole nitrogen. Accordingly, in certain embodiments,preferably R is other than hydrogen in order to direct radiolabeling tothe HetAr group. Mixtures of isomers resulting from ¹¹C-methylation ateither of the pyrazole nitrogens or at the HetAr group can be separatedchromatographically.

Compounds of formula (8) can be prepared as described in Scheme 4.Compounds of formula (10) when reacted with a heteroaromatic alkylhalide of formula (11) under basic conditions, or alternatively, with aheteroaromatic methanol compound of formula (5) under Mitsunobuconditions, will provide compounds of formula (8). Optionally, thefunctional group in the heteroaromatic compounds of formula (11)designated for alkylation with [¹¹C]methyl iodide can be protected asappropriate prior to the alkylation or Mitsunobu reactions of Scheme 4in order to avoid interference with the alkylation or Mitsunobuprocesses. For example, where the heteroaromatic compound of formula(11) is selected from the group consisting of compounds of formulae(11a), (11b) and (11c),

R¹ can be hydrogen, or a nitrogen-protecting group designed for removalafter the ether linkage is established between the compound of formula(10) and the compound of formula (11). Likewise, in certain embodiments,the R substituent group in the compound of formula (10) can be otherthan hydrogen in order to avoid interference with the alkylation orMitsunobu processes.

Compounds of formula (10), wherein R is hydrogen, methyl or ethyl can beprepared as described in Scheme 5. The compound of formula (3), whentreated with 1,1-dimethoxy-N,N-dimethylmethanamine will providecompounds of formula (12). Compounds of formula (12), when treated withhydrazine, methyl hydrazine, or ethyl hydrazine will provide,respectively, compounds of formula (13) wherein R is hydrogen, methyl,or ethyl. The benzyl group of the compound of formula (13) can beremoved via treatment with hydrogen over palladium/carbon, therebyproviding phenolic compounds of formula (10).

¹⁸F-labeled compounds of formula (15), wherein HetAr is as defined informula (I), can be prepared as described in Scheme 6. A sulfonatecompound of formula (14) wherein R⁶ is selected from —CH₃, 4-CH₃-Ph-,and 4-NO₂-Ph-, when treated with [¹⁸F]potassium fluoride in the presenceof Kryptofix-2,2,2 will provide ¹⁸F-labeled compounds of formula (15).The [¹⁸F]fluoride source can be generated in a cyclotron by standardmethods known by those skilled in the art. Although mesylate (R⁶═CH₃),tosylate (R⁶=4-CH₃-Ph), and nosylate (R⁶=4-NO₂-Ph) sulfonate groups arepreferred leaving groups in the fluorination, other suitable leavinggroups can be used as appropriate.

The sulfonate compounds of formula (14) can be prepared as described inScheme 7. The compounds of formula (12), when treated with2-hydroxyethylhydrazine, will provide compounds of formula (16). Thebenzyl group of the compounds of formula (16) can be removed viatreatment with hydrogen over palladium/carbon, thereby providingphenolic compounds of formula (17). Compounds of formula (17), whencombined with either compounds of formula (5) under Mitsunobuconditions, or compounds of formula (11) under basic alkylatingconditions, will provide compounds of formula (18). Treatment of thecompounds of formula (18) with a sulfonyl chloride of formula (19)(e.g., methanesulfonyl chloride) or a sulfonic anhydride of formula (20)(e.g., methanesulfonic anhydride, toluenesulfonic anhydride) in thepresence of a base will provide sulfonate compounds of formula (14).

Compounds of formula (21) wherein HetAr includes a ¹⁸F-label can beprepared as described in Scheme 8. Compounds of formula (8), whereinHetAr comprises a functional group capable of undergoing alkylation(e.g., a primary or secondary amine), when treated with [¹⁸F]fluoroethyltosylate will provide heteroaromatic compounds of formula (21)comprising a ¹⁸F-labeled fluoroethyl group. In instances where thepyrazole nitrogen is unsubstituted (i.e., R═H), radiolabeling can alsooccur at the pyrazole nitrogen. Accordingly, in certain embodiments,preferably R is other than hydrogen in order to direct radiolabeling tothe HetAr group. Mixtures of isomers resulting from ¹⁸F-fluoroethylalkylation at either of the pyrazole nitrogens or at the HetAr group canbe separated chromatographically. The [¹⁸F]fluoroethyl tosylate can beprepared from [¹⁸F]fluoride generated in a cyclotron by methods known tothose skilled in the art.

Non-radiolabeled compounds of formula (I) can be prepared as describedaccording to Schemes 1-8. For example, compounds of formula (I) whereinR is (¹²C)methyl can be prepared by following the synthetic sequences ofSchemes 4 and 5. Compounds of formula (I) wherein R is2-(¹⁹F)fluoroethyl can be prepared by following the synthetic sequencesof Schemes 6 and 7, or alternatively, that of Scheme 9. Compounds offormula (16), when treated with a sulfonyl chloride of formula (19)(e.g., methanesulfonyl chloride) or a sulfonic anhydride of formula (20)(e.g., methanesulfonic anhydride, toluenesulfonic anhydride) willprovide sulfonate compounds of formula (22). Treatment of compounds offormula (22) with tetrabutylammonium fluoride (TBAF) will providedfluorinated compounds of formula (23). The benzyl group of compounds offormula (23) can be removed with hydrogen over palladium/carbon, therebyproviding phenolic compounds of formula (24). The ether linkage betweencompounds of formula (24) and compounds of formula (5) or (11) can beformed with Mitsunobu conditions or alkylating conditions, respectively,to provide compounds of formula (25).

The compounds and intermediates of the invention may be isolated andpurified by methods well-known to those skilled in the art of organicsynthesis. Examples of conventional methods for isolating and purifyingcompounds can include, but are not limited to, chromatography on solidsupports such as silica gel, alumina, or silica derivatized withalkylsilane groups, by recrystallization at high or low temperature withan optional pretreatment with activated carbon, thin-layerchromatography, distillation at various pressures, sublimation undervacuum, and trituration, as described for instance in “Vogel's Textbookof Practical Organic Chemistry”, 5th edition (1989), by Furniss,Hannaford, Smith, and Tatchell, pub. Longman Scientific & Technical,Essex CM20 2JE, England.

Where compounds of the invention have at least one basic nitrogen, thecompounds of the invention may be reacted with an acid at or above roomtemperature to provide the desired salt, which is deposited, andcollected by filtration after cooling. Examples of acids suitable forthe reaction include, but are not limited to tartaric acid, lactic acid,succinic acid, as well as mandelic, atrolactic, methanesulfonic,ethanesulfonic, toluenesulfonic, naphthalenesulfonic, benzensulfonic,carbonic, fumaric, maleic, gluconic, acetic, propionic, salicylic,hydrochloric, hydrobromic, phosphoric, sulfuric, citric, orhydroxybutyric acid, camphorsulfonic, malic, phenylacetic, aspartic,glutamic, and the like.

Compositions of the Invention

The invention also provides pharmaceutical compositions comprising atherapeutically effective amount of a compound of formula (I) incombination with a pharmaceutically acceptable carrier. The compositionscomprise compounds of the invention formulated together with one or morenon-toxic pharmaceutically acceptable carriers. The pharmaceuticalcompositions can be formulated for oral administration in solid orliquid form, for parenteral injection or for rectal administration.

The term “pharmaceutically acceptable carrier”, as used herein, means anon-toxic, inert solid, semi-solid or liquid filler, diluent,encapsulating material or formulation auxiliary of any type. Someexamples of materials which can serve as pharmaceutically acceptablecarriers are sugars such as lactose, glucose and sucrose; starches suchas corn starch and potato starch; cellulose and its derivatives such assodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate;powdered tragacanth; malt; gelatin; talc; cocoa butter and suppositorywaxes; oils such as peanut oil, cottonseed oil, safflower oil, sesameoil, olive oil, corn oil and soybean oil; glycols; such a propyleneglycol; esters such as ethyl oleate and ethyl laurate; agar; bufferingagents such as magnesium hydroxide and aluminum hydroxide; alginic acid;pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol,and phosphate buffer solutions, as well as other non-toxic compatiblelubricants such as sodium lauryl sulfate and magnesium stearate, as wellas coloring agents, releasing agents, coating agents, sweetening,flavoring and perfuming agents, preservatives and antioxidants can alsobe present in the composition, according to the judgment of one skilledin the art of formulations.

The pharmaceutical compositions of this invention can be administered tohumans and other mammals orally, rectally, parenterally,intracisternally, intravaginally, intraperitoneally, topically (as bypowders, ointments or drops), bucally or as an oral or nasal spray. Theterm “parenterally”, as used herein, refers to modes of administrationwhich include intravenous, intramuscular, intraperitoneal, intrasternal,subcutaneous, intraarticular injection and infusion.

Pharmaceutical compositions for parenteral injection comprisepharmaceutically acceptable sterile aqueous or nonaqueous solutions,dispersions, suspensions or emulsions and sterile powders forreconstitution into sterile injectable solutions or dispersions.Examples of suitable aqueous and nonaqueous carriers, diluents, solventsor vehicles include water, ethanol, polyols (propylene glycol,polyethylene glycol, glycerol, and the like, and suitable mixturesthereof), vegetable oils (such as olive oil) and injectable organicesters such as ethyl oleate, or suitable mixtures thereof. Suitablefluidity of the composition may be maintained, for example, by the useof a coating such as lecithin, by the maintenance of the requiredparticle size in the case of dispersions, and by the use of surfactants.

These compositions may also contain adjuvants such as preservativeagents, wetting agents, emulsifying agents, and dispersing agents.Prevention of the action of microorganisms may be ensured by variousantibacterial and antifungal agents, for example, parabens,chlorobutanol, phenol, sorbic acid, and the like. It may also bedesirable to include isotonic agents, for example, sugars, sodiumchloride and the like. Prolonged absorption of the injectablepharmaceutical form may be brought about by the use of agents delayingabsorption, for example, aluminum monostearate and gelatin.

In some cases, in order to prolong the effect of a drug, it is oftendesirable to slow the absorption of the drug from subcutaneous orintramuscular injection. This may be accomplished by the use of a liquidsuspension of crystalline or amorphous material with poor watersolubility. The rate of absorption of the drug then depends upon itsrate of dissolution which, in turn, may depend upon crystal size andcrystalline form. Alternatively, delayed absorption of a parenterallyadministered drug form is accomplished by dissolving or suspending thedrug in an oil vehicle.

Suspensions, in addition to the active compounds, may contain suspendingagents, for example, ethoxylated isostearyl alcohols, polyoxyethylenesorbitol and sorbitan esters, microcrystalline cellulose, aluminummetahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.

If desired, and for more effective distribution, the compounds of theinvention can be incorporated into slow-release or targeted-deliverysystems such as polymer matrices, liposomes, and microspheres. They maybe sterilized, for example, by filtration through a bacteria-retainingfilter or by incorporation of sterilizing agents in the form of sterilesolid compositions, which may be dissolved in sterile water or someother sterile injectable medium immediately before use.

Injectable depot forms are made by forming microencapsulated matrices ofthe drug in biodegradable polymers such as polylactide-polyglycolide.Depending upon the ratio of drug to polymer and the nature of theparticular polymer employed, the rate of drug release can be controlled.Examples of other biodegradable polymers include poly(orthoesters) andpoly(anhydrides). Depot injectable formulations also are prepared byentrapping the drug in liposomes or microemulsions which are compatiblewith body tissues.

The injectable formulations can be sterilized, for example, byfiltration through a bacterial-retaining filter or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium just prior to use.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions may be formulated according to the known artusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation may also be a sterile injectablesolution, suspension or emulsion in a nontoxic, parenterally acceptablediluent or solvent such as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that may be employed are water,Ringer's solution, U.S.P. and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil can beemployed including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid are used in the preparation of injectables.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In such solid dosage forms, one or morecompounds of the invention is mixed with at least one inertpharmaceutically acceptable carrier such as sodium citrate or dicalciumphosphate and/or a) fillers or extenders such as starches, lactose,sucrose, glucose, mannitol, and salicylic acid; b) binders such ascarboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,sucrose, and acacia; c) humectants such as glycerol; d) disintegratingagents such as agar-agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates, and sodium carbonate; e) solutionretarding agents such as paraffin; f) absorption accelerators such asquaternary ammonium compounds; g) wetting agents such as cetyl alcoholand glycerol monostearate; h) absorbents such as kaolin and bentoniteclay; and i) lubricants such as talc, calcium stearate, magnesiumstearate, solid polyethylene glycols, sodium lauryl sulfate, andmixtures thereof. In the case of capsules, tablets and pills, the dosageform may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers insoft and hard-filled gelatin capsules using lactose or milk sugar aswell as high molecular weight polyethylene glycols.

The solid dosage forms of tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells such as entericcoatings and other coatings well known in the pharmaceutical formulatingart. They may optionally contain opacifying agents and can also be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract in a delayedmanner. Examples of materials which can be useful for delaying releaseof the active agent can include polymeric substances and waxes.

Compositions for rectal or vaginal administration are preferablysuppositories which can be prepared by mixing the compounds of thisinvention with suitable non-irritating carriers such as cocoa butter,polyethylene glycol or a suppository wax which are solid at ambienttemperature but liquid at body temperature and therefore melt in therectum or vaginal cavity and release the active compound.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, microemulsions, solutions, suspensions, syrups andelixirs. In addition to the active compounds, the liquid dosage formsmay contain inert diluents commonly used in the art such as, forexample, water or other solvents, solubilizing agents and emulsifierssuch as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethylacetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, dimethylformamide, oils (in particular, cottonseed, groundnut,corn, germ, olive, castor, and sesame oils), glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitan, and mixtures thereof.

Besides inert diluents, the oral compositions can also include adjuvantssuch as wetting agents, emulsifying and suspending agents, sweetening,flavoring, and perfuming agents.

Dosage forms for topical or transdermal administration of a compound ofthis invention include ointments, pastes, creams, lotions, gels,powders, solutions, sprays, inhalants or patches. A desired compound ofthe invention is admixed under sterile conditions with apharmaceutically acceptable carrier and any needed preservatives orbuffers as may be required. Ophthalmic formulation, ear drops, eyeointments, powders and solutions are also contemplated as being withinthe scope of this invention.

The ointments, pastes, creams and gels may contain, in addition to anactive compound of this invention, animal and vegetable fats, oils,waxes, paraffins, starch, tragacanth, cellulose derivatives,polyethylene glycols, silicones, bentonites, silicic acid, talc and zincoxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of thisinvention, lactose, talc, silicic acid, aluminum hydroxide, calciumsilicates and polyamide powder, or mixtures of these substances. Sprayscan additionally contain customary propellants such aschlorofluorohydrocarbons.

Compounds of the invention may also be administered in the form ofliposomes. As is known in the art, liposomes are generally derived fromphospholipids or other lipid substances. Liposomes are formed by mono-or multi-lamellar hydrated liquid crystals that are dispersed in anaqueous medium. Any non-toxic, physiologically acceptable andmetabolizable lipid capable of forming liposomes may be used. Thepresent compositions in liposome form may contain, in addition to thecompounds of the invention, stabilizers, preservatives, and the like.The preferred lipids are the natural and synthetic phospholipids andphosphatidylcholines (lecithins) used separately or together.

Methods to form liposomes are known in the art. See, for example,Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, NewYork, N.Y., (1976), p 33 et seq.

Dosage forms for topical administration of a compound of this inventioninclude powders, sprays, ointments and inhalants. The active compound ismixed under sterile conditions with a pharmaceutically acceptablecarrier and any needed preservatives, buffers or propellants, which canbe required. Opthalmic formulations, eye ointments, powders andsolutions are contemplated as being within the scope of this invention.Aqueous liquid compositions comprising compounds of the invention alsoare contemplated.

The compounds of the invention can be used in the form ofpharmaceutically acceptable salts, esters, or amides derived frominorganic or organic acids. The term “pharmaceutically acceptable salts,esters and amides”, as used herein, refer to carboxylate salts, aminoacid addition salts, zwitterions, esters and amides of compounds offormula (I) which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of humans and lower animalswithout undue toxicity, irritation, allergic response, and the like, arecommensurate with a reasonable benefit/risk ratio, and are effective fortheir intended use.

The term “pharmaceutically acceptable salt” refers to those salts whichare, within the scope of sound medical judgment, suitable for use incontact with the tissues of humans and lower animals without unduetoxicity, irritation, allergic response, and the like, and arecommensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well-known in the art. The salts can be prepared insitu during the final isolation and purification of the compounds of theinvention or separately by reacting a free base function with a suitableorganic acid.

Representative acid addition salts include, but are not limited toacetate, adipate, alginate, citrate, aspartate, benzoate,benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate,digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate,fumarate, hydrochloride, hydrobromide, hydroiodide,2-hydroxyethansulfonate (isethionate), lactate, maleate,methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate,pectinate, persulfate, 3-phenylpropionate, picrate, pivalate,propionate, succinate, tartrate, thiocyanate, phosphate, glutamate,bicarbonate, p-toluenesulfonate and undecanoate. Preferred salts of thecompounds of the invention are the tartrate and hydrochloride salts.

Also, basic nitrogen-containing groups can be quaternized with suchagents as lower alkyl halides such as methyl, ethyl, propyl, and butylchlorides, bromides and iodides; dialkyl sulfates such as dimethyl,diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl,lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkylhalides such as benzyl and phenethyl bromides and others. Water oroil-soluble or dispersible products are thereby obtained.

Examples of acids which can be employed to form pharmaceuticallyacceptable acid addition salts include such inorganic acids ashydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acidand such organic acids as oxalic acid, maleic acid, succinic acid, andcitric acid.

Basic addition salts can be prepared in situ during the final isolationand purification of compounds of this invention by reacting a carboxylicacid-containing moiety with a suitable base such as the hydroxide,carbonate or bicarbonate of a pharmaceutically acceptable metal cationor with ammonia or an organic primary, secondary or tertiary amine.Pharmaceutically acceptable salts include, but are not limited to,cations based on alkali metals or alkaline earth metals such as lithium,sodium, potassium, calcium, magnesium, and aluminum salts, and the like,and nontoxic quaternary ammonia and amine cations including ammonium,tetramethylammonium, tetraethylammonium, methylamine, dimethylamine,trimethylamine, triethylamine, diethylamine, ethylamine and the such as.Other representative organic amines useful for the formation of baseaddition salts include ethylenediamine, ethanolamine, diethanolamine,piperidine, and piperazine.

The term “pharmaceutically acceptable ester”, as used herein, refers toesters of compounds of the invention which hydrolyze in vivo and includethose that break down readily in the human body to leave the parentcompound or a salt thereof. Examples of pharmaceutically acceptable,non-toxic esters of the invention include C₁-to-C₆ alkyl esters andC₅-to-C₇ cycloalkyl esters, although C₁-to-C₄ alkyl esters arepreferred. Esters of the compounds of formula (I) may be preparedaccording to conventional methods. For example, such esters may beappended onto hydroxy groups by reaction of the compound that containsthe hydroxy group with acid and an alkylcarboxylic acid such as aceticacid, or with acid and an arylcarboxylic acid such as benzoic acid. Inthe case of compounds containing carboxylic acid groups, thepharmaceutically acceptable esters are prepared from compoundscontaining the carboxylic acid groups by reaction of the compound withbase such as triethylamine and an alkyl halide, alkyl trifilate, forexample with methyliodide, benzyl iodide, cyclopentyl iodide. They alsomay be prepared by reaction of the compound with an acid such ashydrochloric acid and an alkylcarboxylic acid such as acetic acid, orwith acid and an arylcarboxylic acid such as benzoic acid.

The term “pharmaceutically acceptable amide”, as used herein, refers tonon-toxic amides of the invention derived from ammonia, primary C₁-to-C₆alkyl amines and secondary C₁-to-C₆ dialkyl amines. In the case ofsecondary amines, the amine may also be in the form of a 5- or6-membered heterocycle containing one nitrogen atom. Amides derived fromammonia, C₁-to-C₃ alkyl primary amides and C₁-to-C₂ dialkyl secondaryamides are preferred. Amides of the compounds of formula (I) may beprepared according to conventional methods. Pharmaceutically acceptableamides are prepared from compounds containing primary or secondary aminegroups by reaction of the compound that contains the amino group with analkyl anhydride, aryl anhydride, acyl halide, or aryl halide. In thecase of compounds containing carboxylic acid groups, thepharmaceutically acceptable esters are prepared from compoundscontaining the carboxylic acid groups by reaction of the compound withbase such as triethylamine, a dehydrating agent such as dicyclohexylcarbodiimide or carbonyl diimidazole, and an alkyl amine, dialkylamine,for example with methylamine, diethylamine, piperidine. They also may beprepared by reaction of the compound with an acid such as sulfuric acidand an alkylcarboxylic acid such as acetic acid, or with acid and anarylcarboxylic acid such as benzoic acid under dehydrating conditions aswith molecular sieves added.

The compounds of the invention can be used in the form of apharmaceutically acceptable prodrug. The pharmaceutical compositions ofthe invention can contain compounds of the invention in the form of apharmaceutically acceptable prodrug.

The term “pharmaceutically acceptable prodrug” or “prodrug”, as usedherein, represents those prodrugs of the compounds of the inventionwhich are, within the scope of sound medical judgment, suitable for usein contact with the tissues of humans and lower animals without unduetoxicity, irritation, allergic response, and the like, commensurate witha reasonable benefit/risk ratio, and effective for their intended use.Prodrugs of the invention may be rapidly transformed in vivo to a parentcompound of formula (I), for example, by hydrolysis in blood. A thoroughdiscussion is provided in T. Higuchi and V. Stella, Pro-drugs as NovelDelivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B.Roche, ed., Bioreversible Carriers in Drug Design, AmericanPharmaceutical Association and Pergamon Press (1987), herebyincorporated by reference.

The invention contemplates pharmaceutically active compounds eitherchemically synthesized or formed by in vivo biotransformation tocompounds of formula (I).

Methods of the Invention

The compounds and compositions of the invention are useful for treatingand preventing certain diseases and disorders in humans and animals. Asan important consequence of the ability of the compounds of theinvention to modulate the effects of PDE10A in cells, the compoundsdescribed in the invention can affect physiological processes in humansand animals. In this way, the compounds and compositions described inthe invention are useful for treating and preventing diseases anddisorders modulated by PDE10A. Typically, treatment or prevention ofsuch diseases and disorders can be effected by selectively modulatingPDE10A in a mammal, by administering a compound or composition of theinvention, either alone or in combination with another active agent aspart of a therapeutic regimen.

The compounds of the invention, including but not limited to thosespecified in the examples, possess an affinity for PDE10A and therefore,the compounds of the invention may be useful for the treatment andprevention of diseases or conditions such as certain psychotic disorderssuch as schizophrenia, positive, negative and/or cognitive symptomsassociated with schizophrenia, delusional disorder or substance-inducedpsychotic disorder, anxiety disorders such as panic disorder,obsessive-compulsive disorder, acute stress disorder or generalizedanxiety disorder, obsessive/compulsive disorders, drug addictions,movement disorders such as Parkinson's disease or restless leg syndrome,cognition deficiency disorders such as Alzheimer's disease ormulti-infarct dementia, mood disorders such as depression or bipolardisorders, or neuropsychiatric conditions such as psychosis,attention-deficit/hyperactivity disorder (ADHD) or related attentionaldisorders. The compounds of the invention may be useful for thetreatment of diabetes and related disorders such as obesity byregulating the cAMP signaling system. The compounds of the invention maybe useful in preventing neurons from undergoing apoptosis by raisingcAMP and cGMP levels and, thus, might possess anti-inflammatoryproperties. Neurodegenerative disorders that may be treatable withcompounds of the invention include, but are not limited to, Alzheimer'sdisease, Huntington's disease, Parkinson's disease, multiple sclerosis,stroke and spinal cord injury. The growth of cancer cells is inhibitedby cAMP and cGMP. Thus by raising cAMP and cGMP, compounds of theinvention may also be useful for the treatment of different solid tumorsand hematological malignancies such as renal cell carcinoma or breastcancer.

Compounds of the invention are particularly useful for treating andpreventing a condition or disorder affecting memory or cognition, forexample Alzheimer's disease, attention-deficit hyperactivity disorder,schizophrenia, or the cognitive deficits of schizophrenia or Alzheimer'sdisease.

The hypotheses around the physiological role of PDE10A and thetherapeutic utility of PDE10A inhibitors derive in part from studieswith papaverine, the first extensively profiled pharmacological compoundfor this target. See, e.g., Siuciak et al., “Inhibition of thestriatum-enriched phosphodiesterase PDE10A: A novel approach to thetreatment of psychosis”, Neuropharmacology, v. 51, no. 2, August 2006,pp. 386-396. The PDE10A inhibitor papaverine was shown to be active inseveral antipsychotic models. Papaverine potentiated the catalepticeffect of the D2 receptor antagonist haloperidol in rats, but did notcause catalepsy on its own (WO 03/093499). Papaverine reducedhyperactivity in rats induced by PCP, while reduction ofamphetamine-induced hyperactivity was insignificant (WO 03/093499).These models suggest that PDE10A inhibition has the classicantipsychotic potential that would be expected from theoreticalconsiderations. Also, a method of treating certain neurologic andpsychiatric disorders with the selective PDE10 inhibitor papaverine wasdisclosed (WO 03/0032579). In particular, the method relates topsychotic disorders such as schizophrenia, delusional disorders anddrug-induced psychosis; to anxiety disorders such as panic andobsessive-compulsive disorder; and to movement disorders includingParkinson's disease and Huntington's disease. Papaverine, however hassignificant limitations in this regard with relatively poor potency andselectivity and a very short exposure half-life after systemicadministration. It was found that inhibition of PDE10A reversessubchronic PCP-induced deficits in attentional set-shifting in ratssuggesting that PDE10A inhibitors might alleviate cognitive deficitsassociated with schizophrenia. See, e.g., Rodefer et al., Eur. J.Neurosci., 4 (2005) 1070-1076.

More recent references to the usefulness of PDE10A inhibitors for thetreatment of schizophrenia include: 1) Schmidt, C. J.; Chapin, D. S.;Cianfrogna, J.; Corman, M. L.; Hajos, M.; Harms, J. F.; Hoffman, W. E.;Lebel, L. A.; McCarthy, S. A.; Nelson, F. R.; Proulx-LaFrance, C.;Majchrzak, A. D.; Ramirez, A. D.; Schmidt, K.; Seymour, P. A.; Siuciak,J. A.; Tingley, F. D., III; Williams, R. D.; Verhoest, P. R.; Menniti,F. S. Preclinical Characterization of Selective Phosphodiesterase 10AInhibitors: A New Therapeutic Approach to the Treatment ofSchizophrenia. J. Pharm. Exp. Ther. 2008, 325 (2), 681-690; and 2) JanKehler and Jacob Nielsen, PDE10A Inhibitors: Novel Therapeutic Drugs forSchizophrenia, Current Pharmaceutical Design, 2011, 17, 137-150.

Actual dosage levels of active ingredients in the pharmaceuticalcompositions of this invention can be varied so as to obtain an amountof the active compound(s) that is effective to achieve the desiredtherapeutic response for a particular patient, compositions and mode ofadministration. The selected dosage level will depend upon the activityof the particular compound, the route of administration, the severity ofthe condition being treated and the condition and prior medical historyof the patient being treated. However, it is within the skill of the artto start doses of the compound at levels lower than required to achievethe desired therapeutic effect and to gradually increase the dosageuntil the desired effect is achieved.

When used in the above or other treatments, a therapeutically effectiveamount of one of the compounds of the invention can be employed in pureform or, where such forms exist, in pharmaceutically acceptable salt,ester, amide, prodrug, or radiolabeled form. Alternatively, the compoundcan be administered as a pharmaceutical composition containing thecompound of interest in combination with one or more pharmaceuticallyacceptable carriers. The phrase “therapeutically effective amount” ofthe compound of the invention means a sufficient amount of the compoundto treat disorders, at a reasonable benefit/risk ratio applicable to anymedical treatment. It will be understood, however, that the total dailyusage of the compounds and compositions of the invention will be decidedby the attending physician within the scope of sound medical judgment.The specific therapeutically effective dose level for any particularpatient will depend upon a variety of factors including the disorderbeing treated and the severity of the disorder; activity of the specificcompound employed; the specific composition employed; the age, bodyweight, general health, sex and diet of the patient; the time ofadministration, route of administration, and rate of excretion of thespecific compound employed; the duration of the treatment; drugs used incombination or coincidental with the specific compound employed; andlike factors well known in the medical arts. For example, it is wellwithin the skill of the art to start doses of the compound at levelslower than required to achieve the desired therapeutic effect and togradually increase the dosage until the desired effect is achieved.

For treatment or prevention of disease, the total daily dose of thecompounds of this invention administered to a human or lower animal mayrange from about 0.0003 to about 30 mg/kg/day. For purposes of oraladministration, more preferable doses can be in the range of from about0.0003 to about 1 mg/kg/day. If desired, the effective daily dose can bedivided into multiple doses for purposes of administration;consequently, single dose compositions may contain such amounts orsubmultiples thereof to make up the daily dose.

Compounds and compositions of the invention also are useful asdiagnostic tools. The ability of PET (positron emission tomography) andsPECT (single photon emission computed tomography) to probe the degreeof receptor occupancy in humans and animals by endogenous ligands ordrugs is widely recognized. This constitutes the use of PET as abiomarker to assess efficacy of pharmacological interventions withdrugs. The topic and use of positron-emitting ligands for these purposeshas been generally reviewed, for example in “PET ligands for assessingreceptor occupancy in vivo” Burns, et al. Annual Reports in MedicinalChemistry (2001), 36, 267-276; “Ligand-receptor interactions as studiedby PET: implications for drug development” by Jarmo Hietala, Annals ofMedicine (Helsinki) (1999), 31(6), 438-443; “Positron emissiontomography neuroreceptor imaging as a tool in drug discovery, researchand development” Burns, et al. Current Opinion in Chemical Biology(1999), 3(4), 388-394. The compounds of the invention, synthesized with¹¹C, ¹⁸F, or other positron-emitting isotopes are suitable ligand toolsfor PET; a number of positron-emitting reagents have been synthesized,are available, and are known to those skilled in the art. Especiallysuitable compounds of the invention for this use are those wherein a¹¹CH₃ group can be incorporated in by reaction with ¹¹CH₃I. Also,especially suitable compounds of the use are those wherein a ¹⁸F groupcan be incorporated into the compound by reaction with ¹⁸F-fluorideanion. The incorporation of ¹¹CH₃ can be carried out according to amethod such as that described in Example 10. In a like manner, othercompounds of formula (I) can be prepared for use in PET studies. Theincorporation of ¹⁸F can be carried out according to a method such asthat described in Example 11. In a like manner, other compounds offormula (I) can be prepared for use in PET studies. Among compounds ofthe invention that are suitable for use as ligands for PET studies are³H, ¹⁸F and ¹¹C isotopes of compounds of the invention, including, butnot limited to

-   2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;-   2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,6-naphthyridine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,6-naphthyridine;-   6-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-c]pyridazine;-   6-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-c]pyridazine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazoline;-   2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine;-   3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methylquinazolin-4(3H)-one;-   3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;-   3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;-   3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methylpyrido[3,2-d]pyrimidin-4(3H)-one;-   3[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;-   3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;-   1,1-dioxo-2-methyl-3-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   1,1-dioxo-2-methyl-3-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   1,1-dioxo-2-[¹¹C]methyl-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   1,1-dioxo-2-(2-[¹⁸F]fluoroethyl)-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;-   2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1-methyl-1H-benzo[d]imidazole;-   1-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1H-benzo[d]imidazole;-   2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)oxazolo[5,4-b]pyridine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)oxazolo[5,4-b]pyridine;-   3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;-   2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methyl-3H-imidazo[4,5-b]pyridine;-   3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;-   3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;    and-   2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-5-[³H]benzo[d]oxazole.

The compounds and processes of the invention will be better understoodby reference to the following examples, which are intended as anillustration of and not a limitation upon the scope of the invention.

EXAMPLES

4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol

4-(benzyloxy)-N-methoxy-N-methylbenzamide

A stirred suspension of 4-(benzyloxy)benzoic acid (CAS#1486-51-7,Aldrich #512354, 5 g, 21.91 mmol) and N,N-dimethylformamide (0.254 mL,3.29 mmol) in dichloromethane (50 mL) was chilled to 0° C. To thisstirred mixture was added dropwise oxalyl chloride (3.84 mL, 43.9 mmol).The reaction mixture was stirred for 18 hours, while slowly warming toambient temperature. Volatiles were removed under reduced pressure togive a white solid (5.3 g, 98%). ¹H NMR (300 MHz, CDCl₃) δ 8.11-8.05 (m,2H), 7.45-7.32 (m, 5H), 7.06-7.01 (m, 2H), 5.16 (s, 2H). This crudematerial was used without further purification by adding CH₂Cl₂ (70 mL)and N,O-dimethylhydroxylamine hydrochloride (2.51 g, 25.8 mmol). Thereaction mixture was cooled to 0° C. and treated dropwise with Et₃N(8.98 mL, 64.4 mmol). After 1 h at 0° C., the mixture was stirred atroom temperature (RT) for 18 h. The reaction mixture was filtered freeof insoluble salts, washed with dilute aqueous HCl, then with diluteaqueous sodium carbonate, and dried over MgSO₄. Drying agent was removedby filtration and the filtrate was concentrated under reduced pressureto give a white solid (5.45 g, 93%). ¹H NMR (300 MHz, methanol-d₄) δ7.69-7.62 (m, 2H), 7.47-7.27 (m, 5H), 7.07-7.01 (m, 2H), 5.13 (s, 2H),3.58 (s, 3H), 3.33 (s, 3H). MS (DCI-NH₃) m/z=272 (M+H)⁺, m/z=289(M+NH₄)⁺.

1-(4-(benzyloxy)phenyl)-2-(pyridin-4-yl)ethanone

An oven-dried, 3-neck, 250 mL round bottom flask equipped with amagnetic stirbar, addition funnel, and internal thermometer was cooledto ambient temperature under a stream of dry nitrogen. The flask wascharged with lithium diisopropylamide, 1.8M solution inTHF/heptane/ethylbenzene (22.07 mL, 39.7 mmol), diluted with THF (30mL), and the solution was chilled to 0° C. To this stirred, 0° C.solution was added dropwise via syringe a solution of 4-methylpyridine(3.87 mL, 39.7 mmol) in THF (25 mL). After the addition was complete thereaction mixture was stirred at 0° C. for 30 minutes. The reactionmixture was then further chilled to −78° C. To this stirred, −78° C.solution was added dropwise via the addition funnel a solution of4-(benzyloxy)-N-methoxy-N-methylbenzamide (4.9 g, 18.06 mmol) in THF (30mL). The resulting reaction mixture was stirred at −78° C. for 2 hours.At this point the reaction was quenched with 4.5 equivalents of aceticacid (4.7 mL) added dropwise to the −78° C. reaction mixture. Thereaction was then allowed to slowly warm to ambient temperatureovernight. Desired product had precipitated from the reaction mixture.Saturated aqueous sodium bicarbonate was added to the reaction mixture.The two layers were filtered to collect the white, insoluble product(3.765 g, 68.7%), then the layers were separated. The aqueous layer wasextracted with EtOAc. The combined EtOAc extracts were diluted withCHCl₃ to better solubilize the product, then dried (MgSO₄), andfiltered. The filtrate was concentrated under reduced pressure to give apale yellow solid. This solid was rinsed with Et₂O repeatedly to remove4-methylpyridine. The pale yellow solid weighed 1.456 g (26.7%, 95%overall). ¹H NMR (300 MHz, CDCl₃) δ 9.55 (dd, J=4.5, 1.5, 2H), 8.00-7.94(m, 2H), 7.45-7.31 (m, 5H), 7.19 (d, J=5.9, 2H), 7.05-6.99 (m, 2H), 5.14(s, 2H), 4.22 (s, 2H). MS (DCI-NH₃) m/z=304 (M+H)⁺.

4-(3-(4-(benzyloxy)phenyl)-1-methyl-1H-pyrazol-4-yl)pyridine

Dimethoxymethyl dimethylamine (9.84 mL) was added to a solution ofIntermediate 1B, 1-(4-(benzyloxy)phenyl)-2-(pyridin-4-yl)ethanone (15 g)in toluene (150 mL). The reaction mixture was heated at reflux for 1 h.The solution was cooled to ambient temperature, and concentrated underreduced pressure. The residue was dissolved in EtOH (150 mL) and methylhydrazine (5.27 mL) was added. The resulting solution was heated atreflux for 2 h. After cooling to ambient temperature, the solid residuewas collected by filtration and re-crystallized from EtOAc to yield4-(3-(4-(benzyloxy)phenyl)-1-methyl-1H-pyrazol-4-yl)pyridine (8 g, 47%).

4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol

Pd/C (3 g) was added to a solution of Intermediate 1C,4-(3-(4-(benzyloxy)phenyl)-1-methyl-1H-pyrazol-4-yl)pyridine (7.6 g) inEtOAc/EtOH (35 mL+35 mL). The mixture was stirred in an autoclave at 5atm H₂ for 48 h. Pd/C was filtered off and the filtrate was concentratedunder reduced pressure to yield the crude product. Purification by flashchromatography afforded pure Intermediate 1,4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (5 g, 89%). ¹H NMR(300 MHz, methanol-d₄) δ 8.36 (dd, J=4.7, 1.6, 2H), 7.99 (s, 1H), 7.29(dd, J=4.7, 1.7, 2H), 7.25-7.20 (m, 2H), 6.83-6.77 (m, 2H), 3.95 (s,3H). MS (DCI-NH₃) m/z=252 (M+H)⁺. (Note: Experimental details forIntermediate 1 are also published in Journal of Medicinal Chemistry2009, 52(16), 5188-5196, Compound 24).

4-(1-(2-hydroxyethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol

2-(3-(4-(benzyloxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol

Dimethoxymethyl dimethylamine (23.26 mL) was added to a solution ofIntermediate 1B, 1-(4-(benzyloxy)phenyl)-2-(pyridin-4-yl)ethanone (35.4g) in toluene (400 mL). The reaction mixture was heated at reflux for 1h. The solution was cooled to ambient temperature, and concentratedunder reduced pressure. The residue was dissolved in EtOH (350 mL) and2-hydroxyethylhydrazine (15.82 mL) was added. The resulting solution washeated at reflux for 2 h. After concentration under reduced pressure,the residue was purified by flash column chromatography to yield2-(3-(4-(benzyloxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol (8.5g, 39%).

4-(1-(2-hydroxyethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol

Pd/C (3 g) was added to a solution of Intermediate 2A,2-(3-(4-(benzyloxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol (7.5g) in EtOAc/EtOH (35 mL+35 mL). The mixture was stirred in autoclave at5 atm H₂ for 48 h. Pd/C was filtered off and the filtrate wasconcentrated under reduced pressure to yield the crude product.Purification by flash column chromatography afforded pure Intermediate2, 4-(1-(2-hydroxyethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (5 g,88%).

4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol

2-(3-(4-(benzyloxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate

Intermediate 2,4-(1-(2-hydroxyethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (8.15 g)was dissolved in DCM (100 mL), and NEt₃ (4.59 mL) was added. Thesolution was cooled to 0° C. Methanesulfonyl chloride (2.07 mL) wasadded dropwise, and the mixture was allowed to warm to ambienttemperature. The reaction mixture was washed first with citric acid,then with water. The organic layer was dried (MgSO₄), filtered, andconcentrated under reduced pressure to yield2-(3-(4-(benzyloxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate (8.6 g, 97%).

4-(3-(4-(benzyloxy)phenyl)-1-(2-fluoroethyl)-1H-pyrazol-4-yl)pyridine

Intermediate 3A,2-(3-(4-(benzyloxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate (11 g) was added to a 1M solution of tetrabutylammoniumfluoride in THF (150 mL) and the reaction mixture was stirred overnightat ambient temperature. The reaction mixture was concentrated underreduced pressure and the residue was purified by flash columnchromatography to obtain the desired Intermediate 3B,4-(3-(4-(benzyloxy)phenyl)-1-(2-fluoroethyl)-1H-pyrazol-4-yl)pyridine(2.1 g, 23%) and the side product4-(3-(4-(benzyloxy)phenyl)-1-vinyl-1H-pyrazol-4-yl)pyridine (2.0 g,30%).

4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol

Pd/C (1 g) was added to a solution of Intermediate 3B,4-(3-(4-(benzyloxy)phenyl)-1-(2-fluoroethyl)-1H-pyrazol-4-yl)pyridine(2.1 g) in EtOAc/EtOH (30 mL+30 mL). The mixture was stirred inautoclave at 2.5 atm H₂ for 18 h. Pd/C was filtered off and the filtratewas concentrated under reduced pressure to yield the crude product.Purification by flash column chromatography afforded the pure product,4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (1.46 g,92%). ¹H NMR (300 MHz, methanol-d₄) δ 8.37 (dd, J=4.6, 1.6, 2H), 8.08(s, 1H), 7.31 (dd, J=4.6, 1.7, 2H), 7.27-7.22 (m, 2H), 6.83-6.78 (m,2H), 4.81 (dt, J=47.1, 4.7, 2H), 4.49 (dt, J=26.6, 4.7, 2H). MS(DCI-NH₃) m/z=284 (M+H)⁺. (Note: Alternative preparation experimentaldetails published in Journal of Medicinal Chemistry 2011, 54, 5820-5835,Compound 8b)

2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine

1-(4-hydroxyphenyl)-2-(pyridin-4-yl)ethanone

Intermediate 1B, 1-(4-(benzyloxy)phenyl)-2-(pyridin-4-yl)ethanone (5.22g, 17.21 mmol) and solvent THF (60 mL) were added to 20% Pd(OH)₂—C, wet(1.044 g, 7.43 mmol) in a 250 mL stainless steel pressure bottle. Thereaction mixture was stirred for 3 hr at 30 psi and ambient temperature.HPLC indicated that both starting material and product were present, soMeOH (10 mL) was added and the reaction was run for an additional 1 h.The reaction mixture was filtered through a nylon membrane and thefiltrate was concentrated under reduced pressure to give a pale yellowsolid (3.13 g, 85% yield). Much of the yellow color was removed byrinsing with MeOH. After the MeOH rinses, the solid was rinsed withEt₂O, then dried in a vacuum oven at 50° C. for 4 hours. Thisvacuum-dried sample weighed 2.071 g (56.4%). ¹H NMR (300 MHz, DMSO-d₆) δ10.38 (br s, 1H), 8.52-8.45 (m, 2H), 7.96-7.89 (m, 2H), 7.29-7.24 (m,2H), 6.90-6.83 (m, 2H), 4.35 (s, 2H). MS (DCI-NH₃) m/z=214 (M+H)⁺,m/z=231 (M+NH₄)⁺.

1,5-naphthyridine-2-carbaldehyde

A 100 mL round bottom flask equipped with a condenser (with a calciumsulfate drying tube) and a magnetic stirbar was charged with2-methyl-1,5-naphthyridine (CAS#7675-32-3, Synchem-OHG # CDP146FP1, 433mg, 3.0 mmol). Dioxane (10 mL) was added to give a stirred solution,then selenium dioxide (366 mg, 3.3 mmol) was added and the reactionmixture was heated to reflux with an oil bath. The stirred reactionmixture was maintained at reflux for 2 h, then cooled to ambienttemperature and filtered through diatomaceous earth. The filtrate wasconcentrated under reduced pressure and the residue was purified bycolumn chromatography on an Analogix IF-280 (Varian SF25-60 g, 100:0 to0:100 hexane/EtOAc). Fractions #10-17 were combined and concentratedunder reduced pressure to give a white solid that was dried overnight ina vacuum oven at ambient temperature. The dried solid Intermediate 4B,1,5-naphthyridine-2-carbaldehyde weighed 229 mg (48%). ¹H NMR (300 MHz,CDCl₃) δ 10.25 (d, J=0.9 Hz, 1H), 9.12 (dd, J=4.2, 1.6 Hz, 1H),8.60-8.54 (m, 2H), 8.28 (d, J=8.7 Hz, 1H), 7.77 (dd, J=8.6, 4.2 Hz, 1H).MS (DCI-NH₃) m/z=159 (M+H)⁺, m/z=176 (M+NH₄)⁺.

(1,5-naphthyridin-2-yl)methanol

A 100 mL round bottom flask equipped with a magnetic stirbar was chargedwith Intermediate 4B, 1,5-naphthyridine-2-carbaldehyde (200 mg, 1.265mmol). Ethanol (12.6 mL) was added to give a solution. To this stirredsolution was added, portionwise, sodium borohydride (47.8 mg, 1.265mmol). The reaction mixture was stirred at ambient temperature for 15minutes, then quenched with aqueous sodium bicarbonate. Volatiles wereremoved under reduced pressure and the residue was partitioned betweenEtOAc and water. The aqueous layer was extracted once more with EtOAc,then the combined organic layers were dried (MgSO₄) and filtered. Thefiltrate was concentrated under reduced pressure to give(1,5-naphthyridin-2-yl)methanol as a pale yellow solid that was purifiedby eluting through a plug of silica gel with 100% EtOAc. Afterevaporation of the solvent under reduced pressure, an off white solidwas obtained, which was dried in a vacuum oven at ambient temperaturefor 3 days to give (1,5-naphthyridin-2-yl)methanol (142 mg, 70%). ¹H NMR(300 MHz, methanol-d₄) δ 8.94 (dd, J=4.3, 1.6 Hz, 1H), 8.47-8.40 (m,2H), 7.96 (d, J=8.8 Hz, 1H), 7.79 (dd, J=8.6, 4.3 Hz, 1H), 4.91 (s, 2H).MS (DCI-NH₃) m/z=161 (M+H)⁺, m/z=178 (M+NH₄)⁺.

1-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethanone

Intermediate 4C, (1,5-naphthyridin-2-yl)methanol (142 mg, 0.887 mmol),Intermediate 4A, 1-(4-hydroxyphenyl)-2-(pyridin-4-yl)ethanone (158 mg,0.739 mmol), and triphenylphosphine (310 mg, 1.182 mmol) were dissolvedin dioxane (6 mL). To this stirred solution was added di-tert-butylazodicarboxylate (272 mg, 1.182 mmol). The reaction mixture was stirredovernight at ambient temperature under a dry nitrogen atmosphere. Thereaction mixture was diluted with aqueous sodium bicarbonate andextracted with CHCl₃. The combined organic layers were dried (MgSO₄) andfiltered. The filtrate was concentrated under reduced pressure to give ayellow oil. The oil was purified by column chromatography on an AnalogixIF-280 (Varian SF25-80 g, 100% DCM to 97:3 DCM/2M NH₃ in MeOH).Fractions #10-22 were combined and concentrated under reduced pressureto give1-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethanone asa pale green solid (104.5 mg, 39.8%). ¹H NMR (300 MHz, CDCl₃) δ 9.00(dd, J=4.2, 1.6 Hz, 1H), 8.55 (dd, J=4.5, 1.6 Hz, 2H), 8.48-8.43 (m,1H), 8.39 (ddd, J=8.5, 1.6, 0.9 Hz, 1H), 8.01-7.95 (m, 2H), 7.90-7.86(m, 1H), 7.68 (dd, J=4.5, 1.5 Hz, 2H), 7.12-7.06 (m, 2H), 5.47 (s, 2H),4.22 (s, 2H). MS (DCI-NH₃) m/z=356 (M+H)⁺.

2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine

In a 5 mL round bottom flask equipped with a magnetic stirbar and acondenser with a calcium sulfate drying tube was stirred at reflux for18 hours a mixture of Intermediate 4D,1-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethanone(104 mg, 0.293 mmol) and N,N-dimethylformamide dimethyl acetal (1.0 mL,7.53 mmol). The reaction mixture was checked by TLC (95:5 EtOAc/MeOH).The spot for starting material had been replaced by a lower Rf spot.Volatiles were removed under reduced pressure to give a brown oil,1-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-3-(dimethylamino)-2-(pyridin-4-yl)prop-2-en-1-one(120 mg, 0.292 mmol) that was dissolved in methanol (2.5 mL) and stirredat ambient temperature. Hydrazine monohydrate (0.02127 mL, 0.438 mmol)was added via syringe and the reaction mixture was stirred at reflux for2 hours. Another 1.5 equivalents of hydrazine monohydrate was added andstirring at reflux was continued an additional 2 hours. Volatiles wereremoved under reduced pressure to give a tan solid that was rinsed withwater 3 times then stirred with Et₂O overnight. The Et₂O was decantedaway and the remaining solid was partitioned between CHCl₃ and brine.The aqueous layer was extracted once more with CHCl₃ and the combinedorganic layers were dried (MgSO₄) and filtered. The filtrate wasconcentrated under reduced pressure to give a crude, bright yellowsolid. This solid was purified by column chromatography on an AnalogixIF-280 (Agilent SF15-24 g, 100% DCM to 98:2 DCM/2M NH₃ in MeOH).Fractions #5-20 were combined and concentrated under reduced pressure togive a pale yellow solid. The solid was dissolved in warm CHCl₃ and theresulting solution was filtered and concentrated under reduced pressure.The solid residue was rinsed with Et₂O, then dissolved in a minimum ofhot MeOH. The solution was placed in a 0° C. freezer to inducecrystallization. Intermediate 4,2-((4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridinewas obtained by filtration as white crystals (16.5 mg, 14.9%). ¹H NMR(300 MHz, methanol-d₄) δ 8.98 (dd, J=4.2, 1.6 Hz, 1H), 8.48 (dd, J=8.6,1.8 Hz, 2H), 8.36 (dd, J=4.7, 1.6 Hz, 2H), 8.02 (d, J=8.8 Hz, 1H), 7.97(br s, 1H), 7.82 (dd, J=8.5, 4.3 Hz, 1H), 7.42-7.36 (m, 2H), 7.33 (d,J=5.9 Hz, 2H), 7.16 (d, J=7.3 Hz, 2H), 5.47 (s, 2H). MS (ESI) m/z=380(M+H)⁺.

2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate

2-(chloromethyl)-1,5-naphthyridine

A mixture of 2-methyl-1,5-naphthyridine (CAS#7675-32-3, Synchem-OHG #CDP146FP1, 998 mg, 6.92 mmol), NCS (1109 mg, 8.31 mmol), and benzoylperoxide (84 mg, 0.347 mmol) in CCl₄ (34 mL) was stirred at reflux for17 h. The reaction mixture was checked by TLC (100% EtOAc). Volatileswere removed under reduced pressure and the residue was partitionedbetween EtOAc and saturated aqueous sodium bicarbonate. The organiclayer was washed with brine, dried (MgSO₄), and filtered. The filtratewas concentrated under reduced pressure and the residue was purified bycolumn chromatography on an Analogix IF-280 (Agilent SF15-24 g, 7:3 to3:7 hexane/EtOAc). Fractions #7-8 were combined and concentrated underreduced pressure to give the undesired byproduct,2-(dichloromethyl)-1,5-naphthyridine, as an off-white solid (113 mg,7.7% yield). Fractions #12-18 were combined and concentrated underreduced pressure to give the desired 2-(chloromethyl)-1,5-naphthyridineas an off-white solid (472 mg, 38.2%). ¹H NMR (300 MHz, CDCl₃) δ 8.99(dd, J=4.2, 1.6, 1H), 8.45 (d, J=8.8, 1H), 8.38 (ddd, J=8.5, 1.5, 0.8,1H), 7.85 (d, J=8.7, 1H), 7.66 (dd, J=8.6, 4.2, 1H), 4.86 (s, 2H). MS(DCI-NH₃) m/z=179 (M+H)⁺, m/z=196 (M+NH₄)⁺, m/z=213 (M+NH₄+NH₃)⁺.

2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol

An oven-dried, 50 mL round bottom flask equipped with a magnetic stirbarwas cooled to ambient temperature under a stream of dry nitrogen. Theflask was charged with Intermediate 2,4-(1-(2-hydroxyethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (157 mg,0.560 mmol) and DMF (4 mL) was added to give a solution. To this stirredsolution was added sodium bis(trimethylsilyl)amide, 1.0 M solution inTHF (0.560 mL, 0.560 mmol). After stirring for 15 minutes, the reactionmixture was treated dropwise with a solution of Intermediate 5A,2-(chloromethyl)-1,5-naphthyridine (100 mg, 0.560 mmol) in THF (2 mL).The vial containing this solution was rinsed with DMF (1 mL) and thisrinse was also added to the reaction mixture. The reaction mixture wasstirred under a dry nitrogen atmosphere at ambient temperature for 2hours. An aliquot was partitioned between water and EtOAc. The organiclayer was checked by TLC (95:5 DCM/2M NH₃ in MeOH). A new spot with anRf intermediate between the two starting materials had formed, althoughsome unreacted starting material was evident. The reaction mixture wasstirred an additional 17 h. Volatiles were removed under reducedpressure and the residue was partitioned between CHCl₃ and aqueoussodium carbonate. The aqueous layer was extracted once more with CHCl₃,then the combined organic layers were washed twice with brine. The CHCl₃layer was dried (MgSO₄) and filtered. The filtrate was concentratedunder reduced pressure to give a pink solid. The solid was purified bycolumn chromatography on an Analogix IF-280 (Agilent SF15-24 g, 98:2 to95:5 DCM/2M NH₃ in MeOH). Fractions #5-9 were combined and concentratedunder reduce pressure to give a pale pink solid that was stored in avacuum oven at ambient temperature to provide dry2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol(157.8 mg, 66.6%). ¹H NMR (300 MHz, methanol-d₄) δ 8.98 (dd, J=4.2, 1.5Hz, 1H), 8.51-8.46 (m, 2H), 8.35 (dd, J=4.6, 1.6 Hz, 2H), 8.06 (s, 1H),8.02 (d, J=8.8 Hz, 1H), 7.82 (dd, J=8.6, 4.3 Hz, 1H), 7.41-7.35 (m, 2H),7.29 (dd, J=4.6, 1.6 Hz, 2H), 7.15-7.09 (m, 2H), 5.46 (s, 2H), 4.29 (t,J=5.3 Hz, 2H), 3.95 (t, J=5.3 Hz, 2H). MS (DCI-NH₃) m/z=424 (M+H)⁺.

2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate

Method 1: A stirred solution of Intermediate 5B,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanolin DCM is cooled at 0° C. Pyridine (12 equivalents) and methanesulfonylchloride (8 equivalents) are added and the reaction mixture is stirredat 0° C. for 1 h. The mixture is quenched with water and extracted withmore DCM. The organic solvent is separated, dried (MgSO₄), andconcentrated under reduced pressure. The crude residue is purified bysilica gel column chromatography. The desired fractions are collectedand concentrated under reduced pressure to yield2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate.

Method 2: A solution of Intermediate 5B,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanolin DCM stirred at 0° C. Pyridine (11 equivalents) is added to thereaction mixture followed by methanesulfonic anhydride (8 equivalents)and stirring is continued for 4 h at 0° C. The solvent is evaporated byflushing with nitrogen then the crude mixture is redissolved in MeOH,diluted with water, and purified by solid phase extraction. Residualwater is removed by azeotropic distillation with MeCN, and the mixtureis dried overnight in a vacuum oven at ambient temperature.

2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate

2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol

A mixture of Intermediate 2,4-(1-(2-hydroxyethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (84 mg,0.298 mmol) in DMF (2 mL) was stirred under dry nitrogen while chillingto 0° C. Sodium bis(trimethylsilyl)amide, 1.0 M solution in THF (0.298mL, 0.298 mmol) was added to the reaction mixture, resulting information of a precipitate. The ice/water bath was removed and thereaction mixture was stirred for 15 minutes as much of the precipitatedissolved. A solution of 2-(chloromethyl)benzo[d]oxazole(CAS#41014-43-1, Bionet #12Y-0817, 50 mg, 0.298 mmol) in THF (1 mL) wasthen added dropwise to the reaction mixture, turning it a deep purplecolor. When the addition was complete, the reaction mixture was stirredat 40° C. for 30 minutes. TLC (95:5 DCM/2M NH₃ in MeOH) indicated that ahigher Rf spot had formed so the reaction mixture was diluted withaqueous sodium carbonate and extracted with EtOAc. The organic layer waswashed with brine, dried (MgSO₄), and filtered. The filtrate wasconcentrated under reduced pressure to give a golden oil. The oil waspurified by column chromatography on an Analogix IF-280 (Agilent SF10-4g, 100% DCM to 98:2 DCM/2M NH₃ in MeOH). Fractions #13-17 were combinedand concentrated under reduced pressure to give2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanolas an off-white solid (79 mg, 64.2%). ¹H NMR (300 MHz, methanol-d₄) δ8.34 (dd, J=4.6, 1.6 Hz, 2H), 8.06 (s, 1H), 7.76-7.69 (m, 1H), 7.68-7.61(m, 1H), 7.48-7.35 (m, 4H), 7.28 (dd, J=4.6, 1.6 Hz, 2H), 7.15-7.09 (m,2H), 5.43 (s, 2H), 4.28 (t, J=5.3 Hz, 2H), 3.95 (t, J=5.3 Hz, 2H). MS(ESI+) m/z=413 (M+H)⁺.

2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate

Intermediate 6 is prepared by the methods described for the final stepleading to Intermediate 5, substituting Intermediate 6A,2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanolin place of Intermediate 5B.

5-bromo-2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole

A mixture of Intermediate 3,4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (57 mg,0.201 mmol) and cesium carbonate (197 mg, 0.604 mmol) in DMF (2 mL) wasstirred at ambient temperature under a dry nitrogen atmosphere for 15minutes. A solution of 5-bromo-2-(chloromethyl)benzo[d]oxazole(CAS#110704-48-8, Bionet # GC-0713, 54.6 mg, 0.221 mmol) in THF (0.5 mL)was added dropwise to the reaction mixture. When the addition wascomplete the reaction mixture was stirred at ambient temperature for 74hours. The reaction mixture was diluted with water and extracted withEtOAc (3×30 mL). The combined organic layers were washed with brine(2×50 mL), then dried over MgSO₄. The drying agent was removed byfiltration and the filtrate was concentrated under reduced pressure togive a golden oil that was purified by column chromatography on anAnalogix IF-280 (Agilent SF15-24 g, 100% DCM to 96:4 DCM/2M NH₃ inMeOH). Fractions #7-14 were combined and concentrated under reducedpressure to give5-bromo-2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazoleas a white solid (53.1 mg, 53.5%). ¹H NMR (300 MHz, methanol-d₄) δ 8.36(d, J=6.0, 2H), 8.09 (s, 1H), 7.90 (dd, J=1.6, 0.7, 1H), 7.63-7.55 (m,2H), 7.43-7.36 (m, 2H), 7.29 (dd, J=4.7, 1.6, 2H), 7.15-7.09 (m, 2H),5.43 (s, 2H), 4.81 (dt, J=47.1, 4.7, 2H), 4.51 (dt, J=26.6, 4.9, 1H). MS(DCI-NH₃) m/z=493 (M+H)⁺.

2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate

An oven-dried, 25 mL round bottom flask, equipped with a magneticstirbar, was cooled to ambient temperature under a stream of drynitrogen. The flask was charged with Intermediate 5B,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol(134.5 mg, 0.318 mmol) and p-toluenesulfonic anhydride (114 mg, 0.349mmol). DCM (3 mL) was added to give a solution that was stirred whilecooling with an ice/water bath. Triethylamine (0.0531 mL, 0.381 mmol)was added by syringe and the reaction mixture turned a red-orange color.Stirring at 0° C. was continued for 10 minutes, then the ice/water bathwas removed and the reaction mixture was allowed to reach ambienttemperature. The reaction mixture was stirred at ambient temperature for5 hours. The reaction mixture was diluted with DCM and washed withwater. The organic layer was then washed with dilute aqueous sodiumbicarbonate solution. The organic layer was dried (MgSO₄) and filtered.The filtrate was concentrated under reduced pressure to give a pinksolid that was purified by column chromatography on an Analogix IF-280(Agilent SF15-24 g, 100% EtOAc to 50:50 EtOAc/acetonitrile). Fractions#1-36 were combined and concentrated under reduced pressure to give awhite solid that was stored overnight under a stream of dry nitrogen.The solid was dissolved in DCM and the mixture was filtered. Thefiltrate was transferred to a tared, 4 mL screw cap vial. Solvent wasevaporated to provide a white solid (158 mg, 86% yield). NMR and MS ofthis solid indicated that there was some minor contamination by theN-vinyl-pyrazole byproduct resulting from elimination. This white solidwas dissolved in hot EtOAc. Treatment with Et₂O caused some oiling out.The solution was decanted away and partially concentrated to give2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate as a white solid (67.5 mg, 36.9%) that wascollected by filtration and rinsed with Et₂O. NMR indicated that thecompound was pure with no sign of the N-vinyl-pyrazole contaminant beingpresent. ¹H NMR (300 MHz, CDCl₃) δ 8.99 (dd, J=4.2, 1.6 Hz, 1H), 8.50(s, 2H), 8.44 (d, J=8.8 Hz, 1H), 8.38 (ddd, J=8.5, 1.5, 0.7 Hz, 1H),7.93 (d, J=8.8 Hz, 1H), 7.69-7.64 (m, 2H), 7.60 (s, 1H), 7.33-7.28 (m,2H), 7.22 (d, J=8.0 Hz, 2H), 7.15 (d, J=4.9 Hz, 2H), 7.03-6.98 (m, 2H),5.43 (s, 2H), 4.47-4.39 (m, 4H), 2.32 (s, 3H). MS (+ESI) m/z=578 (M+H)⁺.

2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate

A stirred solution of2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol(71 mg, 0.172 mmol) and p-toluenesulfonic anhydride (61.8 mg, 0.189mmol) in DCM (1.5 mL) in a 4 mL screw cap vial under a dry nitrogenatmosphere was chilled with an ice/water bath. To this stirred reactionmixture was added triethylamine (0.0288 mL, 0.207 mmol) via syringe. Thereaction mixture was stirred at 0° C. for 10 minutes, then the ice/waterbath was removed and stifling was continued at ambient temperature for4.5 hours. A TLC check (80:20 CHCl₃/CH₃CN) indicated that a higher Rfspot had formed. The reaction mixture was washed with water and thenwith aqueous sodium bicarbonate solution. After a brine wash, theorganic layer was dried (MgSO₄) and filtered. The filtrate wasconcentrated under reduced pressure and the residue was purified bycolumn chromatography on an Analogix IF-280 (Agilent SF15-12 g, 60:40CHCl₃/acetonitrile). Fractions #3-8 were combined and concentrated underreduced pressure to give a white solid that was crystallized fromEtOAc/Et₂O. Two crystal batches were combined to provide2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate as white crystals (44 mg, 45%). ¹H NMR (300MHz, CDCl₃) δ 8.50 (d, J=4.2 Hz, 2H), 7.79-7.73 (m, 1H), 7.69-7.64 (m,2H), 7.60 (s, 1H), 7.59-7.54 (m, 1H), 7.42-7.34 (m, 2H), 7.34-7.29 (m,2H), 7.22 (d, J=8.1 Hz, 2H), 7.14 (d, J=5.5 Hz, 2H), 7.07-7.01 (m, 2H),5.35 (s, 2H), 4.47-4.39 (m, 4H), 2.32 (s, 3H). MS (+ESI) m/z=567 (M+H)⁺.

3-methyl-2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one

2-(hydroxymethyl)-3-methylquinazolin-4(3H)-one

The title compound is prepared by the method published in Journal ofOrganic Chemistry 1964, 29, 582-584 (see compound IVa).

3-methyl-2-((4-(2-(pyridin-4-yl)acetyl)phenoxy)methyl)quinazolin-4(3H)-one

The title compound is prepared by the method of Intermediate 4D,substituting Intermediate 10A,2-(hydroxymethyl)-3-methylquinazolin-4(3H)-one, in place of Intermediate4C, (1,5-naphthyridin-2-yl)methanol.

3-methyl-2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one

The title compound is prepared by the method of Intermediate 4,substituting Intermediate 10B,3-methyl-2-((4-(2-(pyridin-4-yl)acetyl)phenoxy)methyl)-quinazolin-4(3H)-one,in place of Intermediate 4D,1-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethanone.

1,1-dioxo-2-methyl-3-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine

(1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazin-3-yl)methanol

The title compound is prepared by a two step procedure.

Step 1: N-methylation of a DMF solution of methyl1,1-dioxo-2H-benzo[e][1,2,4]thiadiazine-3-carboxylate (CAS#1251923-55-3,Enamine # EN300-64179) by iodomethane in the presence of a base such asNaN(TMS)₂ or Cs₂CO₃ provides methyl1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazine-3-carboxylate.

Step 2: Reduction of methyl1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazine-3-carboxylate with areducing agent such as LAH or NaBH₄ provides Intermediate 11A,(1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazin-3-yl)methanol.

1-(4-((1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazin-3-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethanone

The title compound is prepared by the method of Intermediate 4D,substituting Intermediate 11A,(1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazin-3-yl)methanol, in placeof Intermediate 4C, (1,5-naphthyridin-2-yl)methanol.

1,1-dioxo-2-methyl-3-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine

The title compound is prepared by the method of Intermediate 4,substituting Intermediate 11B,1-(4-((1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazin-3-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethanone,in place of Intermediate 4D,1-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethanone.

2-(3-(4-((1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazin-3-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate

1,1-dioxo-3-(chloromethyl)-2-methyl-2H-benzo[e][1,2,4]thiadiazine

The title compound is prepared by diazomethane methylation of1,1-dioxo-3-(chloromethyl)-2H-benzo[e][1,2,4]thiadiazine(CAS#37162-65-5, Enamine # EN300-62803) by the method published inFarmaco, Edicione Scientifica 1966, 21, 430-442 (see compound XVI).

2-(3-(4-((1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazin-3-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol

The title compound is prepared by the method of Intermediate 5B,substituting Intermediate 12A,1,1-dioxo-3-(chloromethyl)-2-methyl-2H-benzo[e][1,2,4]thiadiazine inplace of Intermediate 5A, 2-(chloromethyl)-1,5-naphthyridine.

2-(3-(4-((1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazin-3-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate

The title compound is prepared by the method of Intermediate 8,substituting Intermediate 12B,2-(3-(4-((1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazin-3-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol,in place of Intermediate 5B,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol.

2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine

2-methylpyrido[3,2-d]pyrimidine

Dechlorination of 4-chloro-2-methylpyrido[3,2-d]pyrimidine(CAS#56128-29-1, HDH Pharma, Inc. #16414) by hydrogenolysis in thepresence of catalytic Pd/C provides 2-methylpyrido[3,2-d]pyrimidine.

pyrido[3,2-d]pyrimidine-2-carbaldehyde

Oxidation with selenium dioxide by the method of Intermediate 4B,substituting 2-methylpyrido[3,2-d]pyrimidine, in place of2-methyl-1,5-naphthyridine providespyrido[3,2-d]pyrimidine-2-carbaldehyde.

pyrido[3,2-d]pyrimidin-2-ylmethanol

Reduction with sodium borohydride by the method of Intermediate 4C,substituting pyrido[3,2-d]pyrimidine-2-carbaldehyde, in place ofIntermediate 4B, 1,5-naphthyridine-2-carbaldehyde providespyrido[3,2-d]pyrimidin-2-ylmethanol.

2-(pyridin-4-yl)-1-(4-(pyrido[3,2-d]pyrimidin-2-ylmethoxy)phenyl)ethanone

The title compound is prepared by the method of Intermediate 4D,substituting Intermediate 13C, pyrido[3,2-d]pyrimidin-2-ylmethanol, inplace of Intermediate 4C, (1,5-naphthyridin-2-yl)methanol.

2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine

The title compound is prepared by the method of Intermediate 4,substituting Intermediate 13D,2-(pyridin-4-yl)-1-(4-(pyrido[3,2-d]pyrimidin-2-ylmethoxy)phenyl)ethanone,in place of Intermediate 4D,1-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-2-(pyridin-4-yl)ethanone.

2-(4-(pyridin-4-yl)-3-(4-(pyrido[3,2-d]pyrimidin-2-ylmethoxy)phenyl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate

2-(chloromethyl)pyrido[3,2-d]pyrimidine

The title compound is prepared by the method of Intermediate 5Asubstituting Intermediate 13A, 2-methylpyrido[3,2-d]pyrimidine, in placeof 2-methyl-1,5-naphthyridine.

2-(4-(pyridin-4-yl)-3-(4-(pyrido[3,2-d]pyrimidin-2-ylmethoxy)phenyl)-1H-pyrazol-1-yl)ethanol

The title compound is prepared by the method of Intermediate 5B,substituting Intermediate 14A, 2-(chloromethyl)pyrido[3,2-d]pyrimidine,in place of Intermediate 5A, 2-(chloromethyl)-1,5-naphthyridine.

2-(4-(pyridin-4-yl)-3-(4-(pyrido[3,2-d]pyrimidin-2-ylmethoxy)phenyl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate

The title compound is prepared by the method of Intermediate 8,substituting Intermediate 14B,2-(4-(pyridin-4-yl)-3-(4-(pyrido[3,2-d]pyrimidin-2-ylmethoxy)phenyl)-1H-pyrazol-1-yl)ethanol,in place of Intermediate 5B,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol.

2-(4-(pyridin-4-yl)-3-(4-(quinazolin-2-ylmethoxy)phenyl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate

2-(chloromethyl)quinazoline

The title compound was prepared by the method described in Journal ofthe Chemical Society, C. Organic 1966, 234-239.

Step 1: A solution of 2-aminobenzaldehyde (0.969 g, 8 mmol) and pyridine(1.618 mL, 20.00 mmol) in benzene (8 mL) was stirred at 5° C. under adry nitrogen atmosphere. A solution of chloroacetyl chloride (0.765 mL,9.60 mmol) in benzene (4 mL) was added dropwise to the reaction mixture.When the addition was complete, the reaction mixture was allowed to warmto 20° C., then was stirred at that temperature for 15 minutes. Thereaction mixture was then washed with water (3×20 mL). The combinedaqueous layers were extracted once with EtOAc (15 mL). The combinedorganic layers were dried (Na₂SO₄) and filtered. The filtrate wasconcentrated under reduced pressure to give a pale yellow solid. Thesolid was checked by TLC (9:1 hexane/EtOAc). A new spot with Rf lowerthan the starting material was evident. The crude solid was treated withTHF/Et₂O to provide the intermediate,2-chloro-N-(2-formylphenyl)acetamide, as an off-white solid (892 mg,56.4%) that was collected by filtration. ¹H NMR (300 MHz, d₆-DMSO) δ11.43 (s, 1H), 10.01 (s, 1H), 8.32 (d, J=8.2 Hz, 1H), 7.94 (dd, J=7.7,1.6 Hz, 1H), 7.76-7.69 (m, 1H), 7.39 (dt, J=7.5, 1.0 Hz, 1H), 4.47 (s,2H). MS (DCI-NH₃) m/z=198 (M+H)⁺, m/z=215 (M+NH₄)⁺, m/z=232(M+NH₄+NH₃)⁺.

Step 2: The product of the first step,2-chloro-N-(2-formylphenyl)acetamide (0.869 g, 4.40 mmol) and ammonia,7N solution in methanol (4.4 mL, 30.8 mmol) were stirred together atambient in a sealed tube for 4.5 hours. A TLC (9:1 hexane EtOAc) checkindicated that a new lower Rf spot had formed, however, plenty ofstarting material remained so stirring at ambient temperature wascontinued for another 19.5 hours, during which time a white precipitatehad formed. Volatiles were removed under reduced pressure to give abeige solid that was treated with CHCl₃. The portion that was solublewas checked by TLC (7:3 hexane/EtOAc). The major spot in theCHCl₃-soluble portion was a new one with lower Rf than the startingmaterial. The CHCl₃ mixture was placed in the 0° C. freezer over theweekend. Insoluble material was removed by filtration and the filtratewas concentrated under reduced pressure. The residue was purified bycolumn chromatography on an Analogix IF-280 (Agilent SF10-4 g, 100%CHCl₃). The product eluted in fractions #1-10. The product fractionswere combined and concentrated under reduced pressure to give2-(chloromethyl)quinazoline as a white solid (418 mg, 53.2%). ¹H NMR(300 MHz, CDCL₃) δ 9.45 (s, 1H), 8.09-8.04 (m, 1H), 7.99-7.92 (m, 2H),7.70 (ddd, J=8.0, 6.9, 1.2 Hz, 1H), 4.92 (s, 2H).

2-(4-(pyridin-4-yl)-3-(4-(quinazolin-2-ylmethoxy)phenyl)-1H-pyrazol-1-yl)ethanol

The title compound is prepared by the method of Intermediate 5B,substituting Intermediate 15A, 2-(chloromethyl)quinazoline, in place ofIntermediate 5A, 2-(chloromethyl)-1,5-naphthyridine.

2-(4-(pyridin-4-yl)-3-(4-(quinazolin-2-ylmethoxy)phenyl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate

The title compound is prepared by the method of Intermediate 8,substituting Intermediate 15B,2-(4-(pyridin-4-yl)-3-(4-(quinazolin-2-ylmethoxy)phenyl)-1H-pyrazol-1-yl)ethanol,in place of Intermediate 5B,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethanol.

Example 1

2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine

A stirred solution of Intermediate 1,4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (126 mg, 0.50 mmol)in DMF (3 mL) under a dry nitrogen atmosphere was treated with sodiumbis(trimethylsilyl)amide, 1.0M solution in THF (0.550 mL, 0.550 mmol).The reaction mixture was stirred at ambient temperature for 10 minutes,then a solution of Intermediate 5A, 2-(chloromethyl)-1,5-naphthyridine(107 mg, 0.600 mmol) in THF (2 mL) was added dropwise via syringe. Thereaction mixture was stirred at ambient temperature for 17 hours. Analiquot was partitioned between EtOAc and water. The organic layer waschecked by TLC (95:5 DCM/2M NH₃ in MeOH). A faint spot for the startingphenol remained, but the prominent spot with Rf higher than the startingphenol was evident. The reaction mixture was diluted with aqueous sodiumcarbonate and extracted with EtOAc (2×30 mL). The combined organiclayers were then washed with brine (2×60 mL), dried (MgSO₄), andfiltered. The filtrate was concentrated under reduced pressure and theresidue was purified by column chromatography on an Analogix IF-280(Varian SF25-80 g, 99:1 to 96:4 DCM/2M NH₃ in MeOH). Fractions #16-37were combined and concentrated under reduced pressure. The residue wasdissolved in DCM and the resulting solution was filtered. The filtratewas concentrated under reduced pressure to give2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridineas a white solid (150 mg, 76%). ¹H NMR (300 MHz, methanol-d₄) δ 8.97(dd, J=4.3, 1.6 Hz, 1H), 8.50-8.45 (m, 2H), 8.35 (dd, J=4.6, 1.6 Hz,2H), 8.02 (d, J=9.0 Hz, 1H), 8.00 (s, 1H), 7.81 (dd, J=8.5, 4.3 Hz, 1H),7.39-7.34 (m, 2H), 7.28 (dd, J=4.6, 1.7 Hz, 2H), 7.14-7.08 (m, 2H), 5.45(s, 2H), 3.96 (s, 3H). MS (DCI-NH₃) m/z=394 (M+H)⁺.

Example 2

2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine

A solution of Intermediate 3,4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (142 mg,0.5 mmol) in DMF (2 mL) was stirred at 0° C. under a dry nitrogenatmosphere. Sodium bis(trimethylsilyl)amide, 1.0M solution in THF (0.525mL, 0.525 mmol) was added dropwise to the cold reaction mixture. Afterstirring at 0° C. for 5 minutes, the reaction mixture was treateddropwise with a solution of Intermediate 5A,2-(chloromethyl)-1,5-naphthyridine (107 mg, 0.600 mmol) in THF (1 mL).When the addition was complete, the ice/water bath was removed and thereaction mixture was stirred at ambient temperature for 2 hours. A TLC(95:5 DCM/2M NH₃ in MeOH) check of the reaction mixture indicated thatthe starting phenol had been replaced by a major spot with higher Rf.The reaction mixture was partitioned between aqueous sodium carbonateand EtOAc. The aqueous layer was extracted once more with EtOAc, thenthe combined organic layers were washed twice with brine, dried (MgSO₄),and filtered. The filtrate was concentrated under reduced pressure togive a crude solid that, according to LC/MS (AA+method), was a mixtureof desired product (ID: 10, RT=1.43 min) and a nearby (ID: 12, RT=1.54)minor contaminant (the N-vinyl-pyrazole derivative of the product, whichis the result of base-induced elimination of HF). The crude solid waspurified by column chromatography on an Analogix IF-280 (Agilent SF15-24g, 100% DCM to 98:2 DCM/2M NH₃ in MeOH). Fractions #17-27 were combinedand concentrated under reduced pressure to give a white solid thatconsisted of desired product contaminated with the N-vinyl-pyrazolebyproduct. The material was repurified with a preparative reverse phasechromatography system in (Waters XBridge Prep C18, 5 μm OBD, 50×100 mm,95:5 to 5:95 25 mM aqueous ammonium carbonate/CH₃CN). Fractionscontaining pure product were concentrated under reduced pressure to givea white solid that was left on the rotary evaporator for 15 minutes withthe bath temperature equal to 60° C. The resulting white solid residuewas treated with acetonitrile and residual water was removed viaazeotrope on the rotary evaporator. This process was repeated one moretime, then the white solid was dissolved in dichloromethane, dried(MgSO₄), and filtered. The filtrate was concentrated under reducedpressure to give2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridineas a white solid (132 mg, 62%). ¹H NMR (300 MHz, methanol-d₄) δ 8.97(dd, J=4.2, 1.5 Hz, 1H), 8.48 (d, J=8.6 Hz, 2H), 8.36 (dd, J=4.7, 1.6Hz, 2H), 8.09 (s, 1H), 8.02 (d, J=8.8 Hz, 1H), 7.81 (dd, J=8.5, 4.3 Hz,1H), 7.42-7.35 (m, 2H), 7.29 (dd, J=4.6, 1.6 Hz, 2H), 7.15-7.09 (m, 2H),5.45 (s, 2H), 4.81 (dt, J=47.1, 4.7 Hz, 2H), 4.50 (dt, J=26.6, 4.7 Hz,2H). MS (DCI-NH₃) m/z=426 (M+H)⁺.

Example 3

2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole

A mixture of Intermediate 3,4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (212 mg,0.75 mmol) and cesium carbonate (733 mg, 2.250 mmol) in DMF (3.75 mL)was stirred at ambient temperature for 15 minutes. Dropwise addition ofa solution of 2-(chloromethyl)benzo[d]oxazole (CAS#41014-43-1, Bionet#12Y-0817, 138 mg, 0.823 mmol) in THF (0.5 mL) to the reaction mixturewas followed by stifling at ambient temperature for 16 hours. An aliquotwas partitioned between EtOAc and water and the organic layer waschecked by TLC (98:2 DCM/2M NH₃ in MeOH). The spot for starting phenolwas replaced with a higher Rf spot, so the bulk of the reaction mixturewas partitioned between EtOAc and water. The organic layer was washedwith saturated aqueous sodium carbonate, then washed with brine, thendried (MgSO₄), and finally filtered. The filtrate was concentrated underreduced pressure to give a dark brown oil that was purified by columnchromatography on an Analogix IF-280 (Varian SF25-80 g, 100% DCM to98.5:1.5 DCM/2M NH₃ in MeOH). Fractions #9-12 were combined andconcentrated under reduced pressure and the residue contained product,but also some contaminants. The residue was repurified by columnchromatography (Varian SF25-60 g, 99.5:0.5 DCM/2M NH₃ in MeOH).Fractions containing pure product (#8-17) were combined and concentratedunder reduced pressure to give2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazoleas a tan solid (124.6 mg, 40.1%). ¹H NMR (300 MHz, methanol-d₄) δ 8.35(dd, J=4.7, 1.5, 2H), 8.09 (s, 1H), 7.76-7.69 (m, 1H), 7.68-7.61 (m,1H), 7.48-7.35 (m, 4H), 7.28 (dd, J=4.7, 1.6, 2H), 5.43 (s, 2H), 4.81(dt, J=47.1, 4.7, 2H), 4.50 (dt, J=26.6, 4.7, 2H). MS (DCI-NH₃) m/z=415(M+H)⁺.

Example 4

3-methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one

A mixture of Intermediate 1,4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol (113 mg, 0.450 mmol)and cesium carbonate (390 mg, 1.197 mmol) in DMF (2 mL) was stirred atambient temperature for 15 minutes. A solution of2-(chloromethyl)-3-methylquinazolin-4(3H)-one (CAS#199114-62-0, Enamine# EN300-23745, 100 mg, 0.479 mmol) in DMF/THF (1 mL:1 mL) was addeddropwise to the stirred reaction mixture. When the addition wascomplete, the reaction mixture was stirred at ambient temperature for 20hours. An aliquot was partitioned between water and EtOAc and theorganic layer was checked by TLC (98:2 DCM/2M NH₃ in MeOH). The spot forthe starting phenol was replaced by a higher Rf spot, so the reactionmixture was diluted with water (100 mL) and extracted with EtOAc (2×25mL). The combined organic extracts were washed with brine (2×50 mL),then dried (MgSO₄) and filtered. The filtrate was concentrated underreduced pressure to give an off-white solid that was purified by columnchromatography on an Analogix IF-280 (Agilent SF15-24 g, 100% EtOAc to98:2 EtOAc/MeOH). Fractions #6-28 were combined and concentrated underreduced pressure to give3-methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-oneas a white solid (160.6 mg, 84.3%). ¹H NMR (300 MHz, methanol-d₄) δ 8.34(dd, J=5.0, 1.2, 2H), 8.26-8.21 (m, 1H), 8.00 (s, 1H), 7.87-7.80 (m,1H), 7.75-7.70 (m, 1H), 7.60-7.54 (m, 1H), 7.42-7.35 (m, 2H), 7.27 (dd,J=4.9, 1.4, 2H), 7.19-7.13 (m, 2H), 5.31 (s, 2H), 3.96 (s, 3H), 3.74 (s,3H). MS (DCI-NH₃) m/z=424 (M+H)⁺.

Example 5

1,1-dioxo-2-methyl-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine

The title compound is prepared by the method of Example 1, substitutingIntermediate 12A,1,1-dioxo-3-(chloromethyl)-2-methyl-2H-benzo[e][1,2,4]thiadiazine, inplace of Intermediate 5A, 2-(chloromethyl)-1,5-naphthyridine.

Example 6

1,1-dioxo-3-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2-methyl-2H-benzo[e][1,2,4]thiadiazine

The title compound is prepared by the method of Example 2, substitutingIntermediate 12A,1,1-dioxo-3-(chloromethyl)-2-methyl-2H-benzo[e][1,2,4]thiadiazine, inplace of Intermediate 5A, 2-(chloromethyl)-1,5-naphthyridine.

Example 7

2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine

The title compound is prepared by the method of Example 1, substitutingIntermediate 14A, 2-(chloromethyl)pyrido[3,2-d]pyrimidine, in place ofIntermediate 5A, 2-(chloromethyl)-1,5-naphthyridine.

Example 8

2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine

The title compound is prepared by the method of Example 2, substitutingIntermediate 14A, 2-(chloromethyl)pyrido[3,2-d]pyrimidine, in place ofIntermediate 5A, 2-(chloromethyl)-1,5-naphthyridine.

Example 9

2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazoline

A mixture of Intermediate 3,4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenol, (89 mg,0.314 mmol) and cesium carbonate (307 mg, 0.942 mmol) in DMF (3 mL) wasstirred at ambient temperature for 10 minutes under a dry nitrogenatmosphere. A solution of Intermediate 15A, 2-(chloromethyl)quinazoline,(67.3 mg, 0.377 mmol) in THF (1 mL) was added dropwise to the stirredreaction mixture. After the addition was complete, the reaction mixturewas stirred at ambient temperature for 3.5 hours under a dry nitrogenatmosphere. An aliquot was partitioned between water and EtOAc. Theorganic layer was checked by TLC (95:5 DCM/2M NH₃ in MeOH). The spot forthe starting phenol was replaced by a major higher Rf spot and a fewvery minor spots, so the reaction mixture was partitioned between EtOAcand water. The organic layer was washed twice with brine, then dried(MgSO₄), and filtered. The filtrate was concentrated under reducedpressure and the residue was purified by column chromatography on anAnalogix IF-280 (Varian SF25-80, 100% DCM to 97:3 DCM/2M NH₃ in MeOH).Fractions containing product and no yellow color (#11-32) were combinedand concentrated under reduced pressure. The residue was dissolved inDCM and filtered. The filtrate was concentrated under reduced pressureto give a pale beige amorphous solid (70.2 mg, 52.5%). Fractionscontaining product and yellow color (#33-42) were combined andconcentrated under reduced pressure separately. The residue wasdissolved in DCM and filtered. This filtrate was concentrated underreduced pressure to give a pale yellow amorphous solid, which appearedto be identical (by NMR & MS) to the first batch. Both batches werecombined to give2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazoline(115 mg, 86%). ¹H NMR (300 MHz, methanol-d₄) δ 9.57 (s, 1H), 8.35 (dd,J=4.6, 1.6 Hz, 2H), 8.15 (dt, J=8.1, 1.0 Hz, 1H), 8.08 (s, 1H),8.07-8.01 (m, 2H), 7.83-7.73 (m, 1H), 7.40-7.33 (m, 2H), 7.29 (dd,J=4.7, 1.7 Hz, 2H), 7.15-7.09 (m, 2H), 5.48 (s, 2H), 4.81 (dt, J=47.2,4.7 Hz, 2H), 4.50 (dt, J=26.6, 4.7 Hz, 2H). MS (+ESI) m/z=426 (M+H)⁺.

Example 10

2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridineExample 10A ¹¹CH₃I [¹¹C]methyl iodide

[¹¹C]carbon dioxide is produced by the [¹⁴N(p,α)¹¹C] nuclear reactionusing a nitrogen gas target (containing oxygen) and bombarding withprotons from a cyclotron. Subsequently, [¹¹C]CO₂ is converted bycatalytic reduction (Ni), to [¹¹C]methane. [¹¹C]Methane is thenconverted into [¹¹C]methyl iodide by gas phase iodination with iodine.

Example 10

2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine

To a solution of the labeling precursor, Intermediate 4,2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine(0.5-0.6 mg) in 100 μL of anhydrous N,N-dimethylformamide (DMF) is addedtetrabutylammonium hydroxide solution (0.9-1.0 μL of 1M TBAOH inmethanol). The solution is vortexed for 1 minute then reacted withExample 10A, [¹¹C]methyl iodide at ambient temperature for 5 minutes.The reaction mixture is then loaded onto a semi-preparative column andeluted with 0.1 M ammonium formate (no pH adjust)/acetonitrile (55:45)at 5 mL/min. The product peak is collected, diluted with deionized water(50 mL) and loaded onto a conditioned Classic C-18 SepPak. The SepPak iswashed with deionized water (10 mL), and the product is eluted with EtOH(1 mL) followed by saline (3 mL), through a 33-mm 0.22-μm Millipore GVfilter, into a dose vial containing 7 mL saline and 40 μL of 4.2%NaHCO₃.

Example 11

2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridineExample 11A K[¹⁸F]F-kryptofix 222 complex

[¹⁸F]Fluoride is produced by an [¹⁸O (p,n)¹⁸F] reaction by irradiationof enriched [¹⁸O]H₂O in a niobium target using protons from a cyclotron.After irradiation, the resultant [¹⁸F]F⁻ is separated from [¹⁸O]H₂Ousing a SepPak anion exchange cartridge. [¹⁸F]F⁻ is eluted from thecartridge using a mixture of MeCN (0.3 mL) and Kryptofix 222/K₂CO₃solution (0.45 mL). The solution is evaporated under a stream of heliumat 110° C. by applying conventional heating and further dried byazeotropic distillation using MeCN at a temperature of 110° C.

Example 11

2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine

Method 1: The labeling precursor, Intermediate 5,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate (5 mg, 10 μmol) in DCM (1 mL) is dissolved in anhydrousDMF (1.5 mL) and used (0.3 mL) for direct nucleophilicradiofluorination. The 0-mesyl derivative is added to Example 11A, thedried [¹⁸F]F—/K₂CO₃/Kryptofix 222 complex, produced as described above.The nucleophilic substitution reaction is carried out by conventionalheating at 90° C. for 15 min. Next, the crude mixture is diluted withwater (1.4 mL) and injected onto an HPLC system consisting of asemipreparative C18 column that is eluted with a mixture of 0.05M NaOAcbuffer pH 5.5 and EtOH. UV detection of the HPLC eluate was performed at254 nm. The peak containing the radiolabeled product, Example 11, iscollected then diluted with saline to obtain a final EtOH concentrationof <10%, and the solution is sterile filtered through a 0.22 μm membranefilter. The purity of the radiotracer is analyzed using an analyticalHPLC system consisting of a C18 column eluted with a mixture of 0.05 MNaOAc buffer pH 5.5 and MeCN. UV detection of the HPLC eluate isperformed at 254 nm.

Method 2: The title compound is prepared similar to Method 1 above,substituting Intermediate 8,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate, in place of Intermediate 5,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate.

Example 12

2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-5-[³H]benzo[d]oxazole

The catalyst (10% Pd/C) was weighed into a 5 mL tritium flask.Intermediate 7,5-bromo-2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole,was dissolved in N,N-dimethylacetamide (0.5 mL), then Et₃N was added andthis solution was transferred to the reaction flask. The flask wasattached to the Trisorber, cooled in liquid nitrogen and evacuated. Thetritium gas was generated and admitted to the reaction flask. Thereaction mixture was stirred for 50 min, then the volatiles wereabsorbed on the liquid nitrogen-cooled charcoal trap. The reactionmixture was diluted with methanol (˜2 mL) and filtered. The methanol wasdistilled out in vacuo. This process was repeated three times then theliquid residue taken up in methanol (29.3 mCi). RHPLC analysis [from0.1% TFA: CH₃CN (70:30) to 50% CH₃CN in 20 min to 100% CH₃CN in 22 minhold to 30 min on Phenomenex Luna C18(2), 4.6×250 mm, 1 mL/min, 320 nMUV] showed ˜71% desired product at ˜10.3 min (there was an apparentby-product at 9.5 min, ˜23%). There was <1% unreacted brominatedprecursor. Coinjection of this crude product solution with the unlabeledstandard, lot 1816476-0, showed that it coinjected with the standard at˜10.3 min and that >91% was the desired product (the by-product wasapparently a chromatographic anomaly). The product solution was taken todryness on the vacuum line and the residue taken up in methanol (˜0.25mL). RHPLC (same as before, except no change to 100% CH₃CN) showed >94%product (27.4 mCi). RTLC analysis [DCM:MeOH:conc. NH₄OH (19:1:0.1) onsilica gel] showed >97% product. The product solution was purified bypreparative TLC [one 20×20 cm, 250 micron EM silica gel “G” eluted withDCM:MeOH:con NH₄OH (190:10:1), product elution with ether] to give aproduct solution which was taken to dryness in vacuo. The residue wastaken up in ethanol (10.0 mL, 16.3 mCi, 1.63 mCi/mL). RHPLC showed >99%radiochemical purity (RT ˜10.3 min, two replicates). LC/MS (same assecond column except using 0.1% HOFor) confirmed identity as2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-5-[³H]benzo[d]oxazole.MS m/z=417 (M+H)⁺. Specific activity=20.5 Ci/mmol.

Example 13

2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole

Method 1: The title compound is prepared by the method of Example 11,substituting Intermediate 6,2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate, in place of Intermediate 5,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate.

Method 2: The title compound is prepared similar to Method 1 above,substituting Intermediate 9,2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate, in place of Intermediate 6,2-(3-(4-(benzo[d]oxazol-2-ylmethoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethylmethanesulfonate.

Example 14

3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one

The title compound is prepared by the method of Example 10, substitutingIntermediate 10,3-methyl-2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one,in place of Intermediate 4,2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine.

Example 15

1,1-dioxo-2-methyl-3-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine

The title compound is prepared by the method of Example 10, substitutingIntermediate 11,1,1-dioxo-2-methyl-3-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine,in place of Intermediate 4,2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine.

Example 16

1,1-dioxo-3-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2-methyl-2H-benzo[e][1,2,4]thiadiazine

The title compound is prepared by method 2 of Example 11, substitutingIntermediate 12,2-(3-((4(1,1-dioxo-2-methyl-2H-benzo[e][1,2,4]thiadiazin-3-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate, in place of Intermediate 8,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate.

Example 17

2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine

The title compound is prepared by the method of Example 10, substitutingIntermediate 13,2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine,in place of Intermediate 4,2-((4-(4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine.

Example 18

2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine

The title compound is prepared by method 2 of Example 11, substitutingIntermediate 14,2-(4-(pyridin-4-yl)-3-(4-(pyrido[3,2-d]pyrimidin-2-ylmethoxy)phenyl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate, in place of Intermediate 8,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate.

Example 19

2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazoline

The title compound is prepared by method 2 of Example 11, substitutingIntermediate 15,2-(4-(pyridin-4-yl)-3-(4-(quinazolin-2-ylmethoxy)phenyl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate, in place of Intermediate 8,2-(3-(4-((1,5-naphthyridin-2-yl)methoxy)phenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl)ethyl4-methylbenzenesulfonate.

Determination of Biological Activity

To determine the effectiveness of representative compounds of thisinvention as PDE10A ligands, the following tests were conducted.

Recombinant PDE proteins were used in in vitro enzymatic reaction formeasurement of PDE activity. These recombinant proteins, includingPDE10A (human, rat and mouse PDE10) and isoforms of PDEs 1, 3, 4, and 5,were purchased from commercial vendor BPS Bioscience. The enzymaticactivity of PDEs was determined by cAMP measurement kit from CisBio(IBA) using HTRF technology.

The PDE enzymatic reaction was carried out in assay buffer (20 mMTris-HCl pH7.5, 10 mM MgCl₂, 0.1% bovine serum albumin) containingenzyme and substrate. The PDE enzymes concentration ranged from 10pM-250 pM, depending on each enzyme's specific activity. The substratecyclic nucleotide (cAMP or cGMP) concentration used in the assay was 20nM for PDE10, and 100 nM for other PDEs. The inhibitory effect ofcompound was determined by incubating various concentration of inhibitorin the enzymatic assay. Typically, compound was serial diluted in DMSOthen further diluted in assay buffer. Next, the compound at varyingconcentration was mixed with PDE enzyme. The reaction was initiated byaddition of cyclic nucleotide substrate, and incubated for 60 minutes at29° C. The reaction was stopped by addition of lysis buffer from assaykit. The cAMP-d2 and anti-cAMP cryptate in the lysis buffer detected thelevel of cAMP left from the PDE hydrolysis reaction. The PDE activity isreversely correlated with the amount of cAMP left in the reaction andcan be converted to the percent activity of an uninhibited control(100%). Thus, IC₅₀ value of inhibitor can be obtained by plottinginhibitor concentration against PDE activity at that concentration.

Compounds of the invention are PDE10A ligands that modulate function ofPDE10A. Generally, representative compounds of the inventiondemonstrated binding affinities for the PDE10A of K_(i)<50 nM or <20 nMand frequently <1 nM. For example, Table 1 shows that compounds ofExamples 1-4 and 9, which are representative of compounds of theinvention, demonstrated PDE10 IC₅₀ binding affinities of 1.05 nM, 0.2nM, 4.70 nM, 2.00 nM, and 0.18 nM, respectively.

Table 1 demonstrates additional characteristics of representativecompounds of the invention as compared to three known PDE10A ligands,MP-10, JNJ-41510417, and Janssen B-3 (Tu et al., Bioorg. Med. Chem. 19,2011, 1666-1673; Celen et al., J. Nucl. Med. 51(10), 2010, 1584-1591; WO2011/051324.) As shown, compounds of the invention unexpectedly possesssuperior lipophilic and brain-penetrant properties, and hepatocytehalf-lives as compared to the known compounds. Compounds of theinvention, particularly the compounds of Examples 1-4 and 9, are lesslipophilic than MP-10, JNJ-41510417 and Janssen B-3, as demonstrated byshake flask (SF) log D values. Preferred compounds of the invention haveshake flask log D values of less than 4. Compounds of the invention,particularly the compounds of Examples 1-4, are poorer substrates forP-gp, and thus are more brain-penetrant than the two known compoundsMP-10 and JNJ-41510417, as demonstrated by their lower Efflux Ratio inthe MDCK-MDR1 assay. Preferred compounds of the invention have EffluxRatios of less than 2.3. Compounds of the invention, particularly thecompounds of Examples 1, 2 and 4, have significantly longer humanhepatocyte half-lives than MP-10, JNJ-41510417 and Janssen B-3, asdemonstrated by human Hepatocyte T₁₁₂ values. Longer hepatocytehalf-lives may provide advantages in that formation of brain-penetrant,radiolabeled, phenolic metabolites may be slowed.

Accordingly, compounds of the invention are useful as PDE10A PETligands.

TABLE 1 Rat PK (0.05 mg/kg, iv) MDCK- PDE10 Min. Free MDR1 Hepa- MonkeyIC₅₀ after [brain] Free Efflux Ratio SF tocyte Microsome Compound (nM)dose (ng/g) B/P (P-gp) log D T_(1/2) (min) T_(1/2) (min)

1.68 3 5 0.054 0.098 0.32 0.22 2.51 4.28 R 13.0 H 54.9 7.0 

0.63 3 5 0.168 0.034 0.40 0.19 3.92 4.47 R 15.3 H 41.7 28.0

0.98 3 5 0.323 0.167 0.18 0.26 2.20 4.05 R 9.1  H 19.0 3.1 

1.05 3 5 0.712 0.732 0.43 0.54 0.73 3.68 R 18.7  H 215.0 27.0

0.20 3 5 0.692 0.184 0.20 0.13 1.95 3.71 R 12.0 H 79.0 24.0

4.70 3 5 0.296 0.155 0.55 0.43 2.12 3.92 R 17.6 H 50.6 23.0

2.00 3 5 0.213 0.166 0.14 0.15 1.52 3.49 R 17.2 H 88.5 54.0

0.18 3 5 4.84 3.50 R 13.0 H 53.0 Free B/P = Ratio of free brainconcentration divided by free plasma concentration; SF log D = log Ddetermined by shake flask method; R = rat; H = human

It is understood that the foregoing detailed description andaccompanying examples are merely illustrative and are not to be taken aslimitations upon the scope of the invention, which is defined solely bythe appended claims and their equivalents.

Various changes and modifications to the disclosed embodiments will beapparent to those skilled in the art. Such changes and modifications,including without limitation those relating to the chemical structures,substituents, derivatives, intermediates, syntheses, formulations, ormethods of use of the invention, may be made without departing from thespirit and scope thereof.

1. A compound of formula (I),

or a pharmaceutically acceptable salt, ester, amide, prodrug, orradiolabeled form thereof, wherein R is selected from the groupconsisting of hydrogen, C₁-C₆ alkyl, and C₃-C₈ cycloalkyl; HetAr is aheteroaryl group selected from the group consisting of formula (i) andformula (ii);

--- is absent or a bond; Z¹, Z², Z³, Z⁴, Z⁵, Z⁸, Z⁹, Z¹⁰, Z¹¹, and Z¹²are each independently selected from the group consisting of N and CR²;Z⁶ and Z⁷ are each independently selected from the group consisting ofN, NR¹, CR², CHR³, SO₂, and C═O; Z¹³ is selected from the groupconsisting of NR¹, CHR³, and O; and R¹, R², and R³ are eachindependently selected from the group consisting of hydrogen, halogen,C₁-C₆ alkyl, and C₃-C₈ cycloalkyl; provided that at least two of Z¹, Z²,Z³, Z⁴, Z⁵, Z⁶, and Z⁷ are heteroatoms; and provided that the followingnon-radiolabeled compounds are excluded:2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazoline;and1-methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1H-benzo[d]imidazole.2. The compound of claim 1, wherein said compound comprises aradiolabel.
 3. The compound of claim 1, wherein R comprises aradiolabel.
 4. The compound of claim 1, wherein HetAr comprises aradiolabel.
 5. The compound of claim 1, wherein HetAr is selected fromthe group consisting of:

wherein Z¹, Z⁸, Z¹³, and R¹ are as defined in claim
 1. 6. The compoundof claim 5, wherein HetAr is


7. The compound of claim 6, wherein R is C₁-C₆ alkyl.
 8. (canceled) 9.The compound of claim 5, wherein HetAr is


10. The compound of claim 9, wherein R is C₁-C₆ alkyl.
 11. (canceled)12. The compound of claim 5, wherein HetAr is


13. The compound of claim 12, wherein R is C₁-C₆ alkyl.
 14. (canceled)15. The compound of claim 5, wherein HetAr is


16. The compound of claim 15, wherein R is C₁-C₆ alkyl.
 17. (canceled)18. The compound of claim 5, wherein HetAr is


19. The compound of claim 18, wherein R is C₁-C₆ alkyl.
 20. (canceled)21. The compound of claim 5, wherein HetAr is


22. The compound of claim 21, wherein Z¹ is CH; R¹ is C₁-C₆ alkyl; and Ris C₁-C₆ alkyl.
 23. The compound of claim 21, wherein Z¹ is N; R¹ isC₁-C₆ alkyl; and R is C₁-C₆ alkyl.
 24. (canceled)
 25. The compound ofclaim 5, wherein HetAr is


26. The compound of claim 25, wherein Z¹ is CH; R¹ is C₁-C₆ alkyl; and Ris C₁-C₆ alkyl.
 27. The compound of claim 25, wherein Z¹ is N; R¹ isC₁-C₆ alkyl; and R is C₁-C₆ alkyl.
 28. (canceled)
 29. The compound ofclaim 5, wherein HetAr is


30. The compound of claim 29, wherein Z⁸ is CH; Z¹³ is O; and R is C₁-C₆alkyl.
 31. The compound of claim 29, wherein Z⁸ is N; Z¹³ is O; and R isC₁-C₆ alkyl.
 32. The compound of claim 29, wherein Z⁸ is CH; Z¹³ is NR¹;R¹ is C₁-C₆ alkyl; and R is C₁-C₆ alkyl.
 33. The compound of claim 29,wherein Z⁸ is N; Z¹³ is NR³; R¹ is C₁-C₆ alkyl; and R is C₁-C₆ alkyl.34. (canceled)
 35. A pharmaceutical composition comprising atherapeutically effective amount of a compound of formula (I) accordingto claim 1, or a pharmaceutically acceptable salt, ester, amide,prodrug, or radiolabeled form thereof, in combination with apharmaceutically acceptable carrier.
 36. (canceled)
 37. (canceled) 38.(canceled)
 39. A method for imaging PDE10A in a mammal comprisingadministering to a subject an effective amount of a compound of claim 1,or a pharmaceutically acceptable salt, ester, amide, prodrug, orradiolabeled form thereof.
 40. A method of treating or preventing acondition or disorder selected from the group consisting ofschizophrenia, cognitive symptoms associated with schizophrenia,delusional disorder, substance-induced psychotic disorder, anxietydisorders, panic disorder, obsessive-compulsive disorder, acute stressdisorder, generalized anxiety disorder, drug addictions, movementdisorders, Parkinson's disease, restless leg syndrome, cognitiondeficiency disorders, Alzheimer's disease, multi-infarct dementia, mooddisorders, depression, bipolar disorders, neuropsychiatric conditions,psychosis, attention-deficit/hyperactivity disorder (ADHD), attentionaldisorders, diabetes, obesity, inflammatory disorders, Huntington'sdisease, multiple sclerosis, stroke, spinal cord injury, cancer, renalcell carcinoma, and breast cancer, comprising administering to a subjectin need thereof a therapeutically effective amount of a compound offormula (I) according to claim 1, or a pharmaceutically acceptable salt,ester, amide, prodrug, or radiolabeled form thereof.
 41. The method ofclaim 39, wherein the compound is selected from the group consisting of:2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,6-naphthyridine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,6-naphthyridine;6-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-c]pyridazine;6-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-c]pyridazine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazoline;2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine;3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methylquinazolin-4(3H)-one;3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methylpyrido[3,2-d]pyrimidin-4(3H)-one;3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;1,1-dioxo-2-methyl-3-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;1,1-dioxo-2-methyl-3-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;1,1-dioxo-2-[¹¹C]methyl-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;1,1-dioxo-2-(2-[¹⁸F]fluoroethyl)-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1-methyl-1H-benzo[d]imidazole;1-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1H-benzo[d]imidazole;2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)oxazolo[5,4-b]pyridine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)oxazolo[5,4-b]pyridine;3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methyl-3H-imidazo[4,5-b]pyridine;3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;and2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-5-[³H]benzo[d]oxazole.42. The method of claim 41, wherein the compound is selected from thegroup consisting of:2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;and2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole.43. A compound or a pharmaceutically acceptable salt thereof, whereinthe compound is selected from the group consisting of:2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,5-naphthyridine;2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,6-naphthyridine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1,6-naphthyridine;6-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-c]pyridazine;6-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-c]pyridazine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazoline;2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidine;3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methylquinazolin-4(3H)-one;3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinazolin-4(3H)-one;3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methylpyrido[3,2-d]pyrimidin-4(3H)-one;3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)pyrido[3,2-d]pyrimidin-4(3H)-one;1,1-dioxo-2-methyl-3-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;1,1-dioxo-2-methyl-3-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;1,1-dioxo-2-[¹¹C]methyl-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;1,1-dioxo-2-(2-[¹⁸F]fluoroethyl)-3-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-2H-benzo[e][1,2,4]thiadiazine;2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1-methyl-1H-benzo[d]imidazole;1-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-1H-benzo[d]imidazole;2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl) phenoxy)methyl)oxazolo[5,4-b]pyridine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl) oxazolo[5,4-b]pyridine;3-methyl-2-((4-(1-[¹¹C]methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;2-((4-(1-(2-[¹⁸F]fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3-methyl-3H-imidazo[4,5-b]pyridine;3-[¹¹C]methyl-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;3-(2-[¹⁸F]fluoroethyl)-2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-3H-imidazo[4,5-b]pyridine;and2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)-5-[³H]-benzo[d]oxazole.